þ
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
|
Delaware
|
11-2920559
|
|
(State of incorporation)
|
(I.R.S. Employer Identification No.)
|
Securities registered pursuant to Section 12(b) of the Act:
|
NONE
|
Securities registered pursuant to Section 12(g) of the Act:
|
Common Stock, $.001 par value
|
Large accelerated filer o | Accelerated filer o | Non - accelerated filer o | Smaller reporting company þ |
Item Number
|
Page Number
|
||||
PART I | |||||
1. |
Business
|
3 | |||
1A. |
Risk factors
|
9 | |||
1B |
Unresolved Staff Comments
|
13 | |||
2. |
Properties
|
13 | |||
3. |
Legal Proceedings
|
13 | |||
4. |
Mine Safety Disclosures
|
13 | |||
PART II | |||||
5. |
Market for Cicero Common Stock and Related Shareholder Matters
|
14 | |||
6. |
Selected Financial Data
|
15 | |||
7. |
Management's Discussion and Analysis of Financial Condition and Results of Operations
|
15 | |||
7A. |
Quantitative and Qualitative Disclosures About Market Risk
|
24 | |||
8. |
Financial Statements and Supplementary Data
|
24 | |||
9. |
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
24 | |||
9A. |
Controls and Procedures
|
24 | |||
9B. |
Other Information
|
25 | |||
PART III | |||||
10. |
Directors, Executive Officers and Corporate Governance
|
26 | |||
11. |
Executive Compensation
|
29 | |||
12. |
Security Ownership of Certain Beneficial Owners and Management
|
35 | |||
13. |
Certain Relationships and Related Transactions, and Director Independence
|
38 | |||
14. |
Principal Accountant Fees and Services
|
39 | |||
PART IV | |||||
15. |
Index Exhibits and Financial Statement Schedules
|
40 | |||
SIGNATURES
|
44 | ||||
INDEX TO FINANCIAL STATEMENTS
|
F-1 |
●
|
Business Process Outsourcers
- use our software solution in contact centers to provide real time integration among existing back-office systems, eliminate redundant data entry, shorten call times, provide real-time data access and enhance customer service and service levels.
|
●
|
A financial institution
- uses our software solution to provide real-time integration among market data, customer account information, existing back-office systems and other legacy applications, eliminate redundant data entry, provide real-time data access and processing, and enhance customer service and service levels.
|
●
|
An insurance company
- uses our software solution to integrate their customer information systems with over thirty software applications including a CRM application.
|
●
|
A law enforcement organization
- uses our software solution to streamline and automate support for arrests and investigations while merging federal, state and local systems within a unified process.
|
●
|
Product functionality and features;
|
●
|
Availability and quality of support services;
|
●
|
Ease of product implementation;
|
●
|
Price;
|
●
|
Product reputation; and
|
●
|
Our financial stability.
|
●
|
Portal software offers the ability to aggregate information at a single point, but not the ability to integrate transactions from a myriad of information systems on the desktop. Plumtree is a representative company in the market.
|
●
|
Middleware software provides integration of applications through messages and data exchange implemented typically in the middle tier of the application architecture. This approach requires modification of the application source code and substantial infrastructure investments and operational expense. Reuters, TIBCO and IBM MQSeries are competitors in the middleware market.
|
●
|
CRM software offers application tools that allow developers to build product specific interfaces and custom applications. This approach is not designed to be product neutral and is often dependent on deep integration with our technology. Siebel and Salesforce.com are representative products in the CRM software category.
|
●
|
Recently, there have been several companies that offer capabilities similar to our software in that these companies advertise that they integrate applications without modifying the underlying code for those applications. OpenSpan is one company who advertises that they can non-invasively integrate at the point of contact or on the desktop.
|
●
|
make a special suitability determination for purchasers of our shares;
|
●
|
receive the purchaser's written consent to the transaction prior to the purchase; and
|
●
|
deliver to a prospective purchaser of our stock, prior to the first transaction, a risk disclosure document relating to the penny stock market.
|
2011
|
2010
|
|||||||||||||||
Quarter
|
High
|
Low
|
High
|
Low
|
||||||||||||
First
|
$ | 0.08 | $ | 0.05 | $ | 0.20 | $ | 0.08 | ||||||||
Second
|
$ | 0.12 | $ | 0.06 | $ | 0.20 | $ | 0.12 | ||||||||
Third
|
$ | 0.10 | $ | 0.05 | $ | 0.13 | $ | 0.08 | ||||||||
Fourth
|
$ | 0.06 | $ | 0.03 | $ | 0.08 | $ | 0.05 |
Debt
|
Interest
|
Series B Dividends
|
Common Stock
|
|||||||||||||
Launny Steffens
|
$ | 3,000,000 | $ | -- | $ | 165,333 | 21,102,222 | |||||||||
SOAdesk, LLC
|
300,000 | -- | -- | 2,000,000 | ||||||||||||
Private Investors
|
243,502 | 26,372 | -- | 1,799,155 | ||||||||||||
Scott Lustgarten
|
-- | 3,107 | 25,833 | 192,934 | ||||||||||||
Ahab Partner L.P.
|
-- | -- | 32,292 | 215,278 | ||||||||||||
Don Peppers
|
-- | -- | 30,578 | 203,852 | ||||||||||||
Ahab International Ltd.
|
-- | -- | 10,764 | 71,759 | ||||||||||||
Mark Landis
|
-- | 3,534 | -- | 23,562 | ||||||||||||
$ | 3,543,502 | $ | 33,013 | $ | 264,800 | 25,608,762 |
Plan Category
|
Number of Securities to
be issued upon exercise of
outstanding options
|
Weighted-average
exercise price of
outstanding options
|
Number of securities
remaining available under
equity compensation plans
(excluding securities reflected
in the first column)
|
|||||||||
Equity compensation plans approved by stockholders
|
4,296,193 | $ | 0.39 | 224,857 | ||||||||
Equity compensation plans not approved by stockholders
|
-0- | -- | -0- |
Years Ended December 31,
|
||||||||
2011
|
2010
|
|||||||
Revenue:
|
||||||||
Software
|
20.8 | % | 36.5 | % | ||||
Maintenance
|
47.3 | % | 48.0 | % | ||||
Services
|
31.9 | % | 15.5 | % | ||||
Total
|
100.0 | % | 100.0 | % | ||||
Cost of revenue:
|
||||||||
Software
|
21.5 | % | 22.6 | % | ||||
Maintenance
|
3.5 | % | 4.9 | % | ||||
Services
|
32.7 | % | 30.6 | % | ||||
Total
|
57.7 | % | 58.1 | % | ||||
Gross margin
|
42.3 | % | 41.9 | % | ||||
Operating expenses:
|
||||||||
Sales and marketing
|
58.2 | % | 66.5 | % | ||||
Research and product development
|
29.8 | % | 29.4 | % | ||||
General and administrative
|
36.5 | % | 42.3 | % | ||||
Total
|
124.5 | % | 138.2 | % | ||||
Loss from operations
|
(82.2 | )% | (96.3 | )% | ||||
Other income/(expense), net
|
(9.1 | )% | 80.9 | % | ||||
Net loss
|
(91.3 | )% | (15.4 | )% |
2011
|
2010
|
|||||||
United States
|
100 | % | 100 | % |
Name
|
Age
|
Position(s)
|
|||
John L Steffens
|
70 |
Director and Chairman
|
|||
John Broderick
|
62 |
Director and Chief Executive Officer/Chief Financial Officer
|
|||
Antony Castagno
|
44 |
Director and Chief Technology Officer
|
|||
Mark Landis
|
70 |
Director
|
|||
Bruce W. Hasenyager
|
70 |
Director
|
|||
Jay R. Kingley
|
51 |
Director
|
|||
Charles B. Porciello
|
76 |
Director
|
|||
Bruce D. Miller
|
61 |
Director
|
|||
John W. Atherton
|
69 |
Director
|
|||
Don Peppers
|
61 |
Director
|
●
|
Setting the total compensation of our Chief Executive Officer and evaluating his performance based on corporate goals and objectives;
|
●
|
Reviewing and approving the Chief Executives Officer’s decisions relevant to the total compensation of the Company’s other executive officer;
|
●
|
Making recommendations to the Board of Directors with respect to equity-based plans in order to allow us to attract and retain qualified personnel; and
|
●
|
Reviewing director compensation levels and practices, and recommending, from time to time, changes in such compensation levels and practices of the Board of Directors.
|
●
|
Base salary;
|
●
|
Non-equity incentive plan compensation;
|
●
|
Long-term incentive compensation; and
|
●
|
Other benefits
|
Name and
Principal
Position
|
Fiscal
Year
|
Salary
|
Stock
Awards
|
Option Awards
(1)
|
Non- Equity
Incentive
Plan
Compensation
(2)
|
All Other
Compensation
(3)
|
Total
|
|||||||||||||||||||
John P. Broderick
Chief Executive Officer Chief /Financial Officer, Corporate Secretary
|
2011
|
$ | 175,000 | -- | -- | $ | 25,000 | $ | 6,030 | $ | 206,030 | |||||||||||||||
2010
|
$ | 175,000 | -- | $ | 6,668 | $ | 25,000 | $ | 10,943 | $ | 217,611 | |||||||||||||||
Antony Castagno
Chief Technology Officer *
|
2011
|
$ | 150,000 | -- | -- | -- | $ | 5,402 | $ | 155,402 | ||||||||||||||||
2010
|
$ | 150,000 | -- | $ | 6,668 | -- | $ | 5,465 | $ | 162,133 | ||||||||||||||||
|
* Mr. Castagno joined our Company in January 2010.
|
(1)
|
Represents the aggregate grant date fair value of stock option awards granted in the respective fiscal year as computed in accordance with FASB ASC Topic 718, Compensation — Stock Compensation. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model.
|
(2)
|
Non-equity incentive plan compensation includes a bonus for certain revenue transactions for named executive earned during fiscal year ended December 31, 2011 and 2010. The revenue transaction was the acceptance of the first contract greater than $300,000 for each fiscal year.
|
(3)
|
Other compensation includes the Company’s portion of major medical insurance premiums and long term disability premiums for named executives during fiscal year ended December 31, 2011 and 2010, respectively.
|
Option Awards
|
Stock Awards
|
||||||||||||||||||||
Name
|
Number of Securities Underlying Unexercised Options # Exercisable
(Vested)
|
Number of Securities Underlying Unexercised Unearned Options# Unexercisable
(Unvested)
|
Option Exercise price ($)
|
Option Expiration date
|
Number of Shares of Stock That Have Not Vested
|
Market Value of Shares of Stock That Have Not Vested
|
|||||||||||||||
John P. Broderick
|
1,000 | (1) | -- | $ | 39.00 |
07/08/2012
|
|||||||||||||||
4,950 | (2) | -- | $ | 26.00 |
04/24/2013
|
||||||||||||||||
5,000 | (3) | -- | $ | 31.00 |
02/18/2014
|
||||||||||||||||
549,360 | (4) | -- | $ | 0.51 |
08/17/2017
|
||||||||||||||||
50,000 | (5) | 25,000 | (5) | $ | 0.09 |
08/20/2020
|
|||||||||||||||
549,630 | (6) | $ | 54,963 | ||||||||||||||||||
Antony Castagno
|
50,000 | (5) | 25,000 | (5) | $ | 0.09 |
08/20/2020
|
(1)
|
These options were granted on July 8, 2002. This stock option vested and became exercisable in three equal annual installments with the first installment vesting on July 8, 2002.
|
(2)
|
These options were granted on April 24, 2003. This stock option vested and became exercisable in three equal annual installments with the first installment vesting on April 24, 2003.
|
(3)
|
These options were granted on February 18, 2004. This stock option vested and became exercisable in three equal annual installments with the first installment vesting on February 18, 2004.
|
(4)
|
These options were granted on August 17, 2007. This stock option vests in three equal installments with the first installment vesting on August 17, 2007.
|
(5)
|
These options were granted on August 20, 2010. This stock option vests in three equal installments with the first installment vesting on August 20, 2010.
|
(6)
|
These are restricted stock granted on August 17, 2007. The shares will vest to him upon his resignation or termination or a change of control.
|
Base Salary
|
Restricted Shares Award
|
Deferred Compensation
|
Total Compensation and Benefits
|
|||||||||||||
John P. Broderick
|
||||||||||||||||
Death
|
$ | -- | $ | 60,459 | $ | 175,000 | $ | 235,459 | ||||||||
Disability
|
-- | 60,459 | 175,000 | 235,459 | ||||||||||||
Involuntary termination without cause
|
175,000 | 60,459 | 175,000 | 410,459 | ||||||||||||
Change in Control
|
175,000 | 60,459 | 175,000 | 410,459 | ||||||||||||
Antony Castagno
|
||||||||||||||||
Involuntary termination without cause
|
75,000 | -- | -- | 75,000 |
Name of Beneficial Owner
|
No. of Common Shares
|
% of Class
|
No. of Series A1 Shares
|
% of Class
|
No. of Series B Shares
|
% of Class
|
% of Combined Classes
|
|||||||||||||||||||||
John L. Steffens (1)
|
28,315,481 | 37.7 | % | 14.832 | 1.0 | % | 6,400.00 | 61.5 | % | 42.6 | % (2) | |||||||||||||||||
Jonathan Gallen (3)
|
9,699,840 | 13.2 | % | -- | * | 1,667.00 | 16.0 | % | 15.1 | % (4) | ||||||||||||||||||
Mark and Carolyn P. Landis (5)
|
3,781,384 | 5.2 | % | 1,326.136 | 86.0 | % | -- | * | 6.9 | % (6) | ||||||||||||||||||
SOAdesk LLC
|
5,168,860 | 7.1 | % | -- | * | 8,240.59 | 44.2 | % | 16.5 | % (7) | ||||||||||||||||||
Bruce Miller
|
2,289,322 | 3.1 | % | -- | * | -- | * | 3.1 | % (8) | |||||||||||||||||||
Don Peppers
|
899,179 | 1.2 | % | -- | * | 1,333.33 | 12.8 | % | 3.0 | % (9) | ||||||||||||||||||
John P. Broderick
|
1,162,918 | 1.6 | % | -- | * | -- | * | 1.6 | % (10) | |||||||||||||||||||
John W. Atherton
|
163,451 | * | -- | * | -- | * | * | (11) | ||||||||||||||||||||
Bruce W. Hasenyager
|
48,319 | * | -- | * | -- | * | * | (12) | ||||||||||||||||||||
Charles Porciello
|
94,953 | * | -- | * | -- | * | * | (13) | ||||||||||||||||||||
Antony Castagno
|
50,000 | * | -- | * | -- | * | * | (14) | ||||||||||||||||||||
Jay R. Kingley
|
16,667 | * | -- | * | -- | * | * | (15) | ||||||||||||||||||||
Scott Lustgarten
|
443,934 | * | -- | * | 1,000.00 | 9.6 | % | 1.9 | (16) | |||||||||||||||||||
All current directors and executive officers as a group (10 persons)
|
36,821,64 | 48.0 | % | 1,340.968 | 87.0 | % | 7,733.33 | 74.4 | % | 53.4 | %(17) |
*
|
Represents less than one percent of the outstanding shares.
|
1.
|
The address of John L. Steffens is 65 East 55
th
Street, New York, N.Y. 10022.
|
2.
|
Includes 26,262,529 shares of common stock, 14,832 common shares issuable upon conversion of the Series A-1 Convertible Preferred Stock, 6,400,000 common shares issuable upon conversion of the Series B Convertible Preferred Stock, and 2,038,285 shares issuable upon the exercise of warrants and 14,667 shares subject to stock options. The exercise prices of the warrants are as follows: 188,285 at $0.18 per share, 250,000 at $0.20 per share and 1,600,000 at $0.25. The exercise price of the stock options is 8,000 at $0.51 per share and 6,667 at $0.09 per share.
|
3.
|
The address of Mr. Gallen is 299 Park Avenue New York, New York 10171.
|
4.
|
Ahab Partner, L.P. (“Partners”), Ahab International, Ltd. (“International”), Queequeg Partners, L.P. (“Queequeg”) and Queequeg, Ltd. (“Limited,” and collectively with Partners, International, and Queequeg, , the “Funds”) held in aggregate 9,283,173 shares of common stock, 1,667,000 common shares issuable upon conversion of the Series B Convertible Preferred Stock and warrants to acquire 416,667 shares of common stock. The exercise prices of the warrants are 416,667 at $0.25. Jonathan Gallen possesses the sole power to vote and the sole power to direct the disposition of all securities of the Company held by the Funds. In addition, Jonathan Gallen held the power to direct the disposition of 100,000 shares of common stock held in private investment account. Accordingly, for the purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Gallen may be deemed to beneficially own 11,079,803 shares of common stock of the Company.
|
5.
|
The address of Mark and Carolyn P. Landis is 503 Lake Drive, Princeton, New Jersey 08540.
|
6.
|
Includes 3,771,717 shares of common stock, 1,326,136 common shares issuable upon conversion of the Series A-1 Convertible Preferred Stock and 14,667 shares subject to stock options. The exercise price of the stock options is 5,000 at $0.51 per share and 4,667 at $0.09 per share. Disclaims beneficial ownership of 5,000 shares because they are anti-dilutive.
|
7.
|
Includes 2,000,000 shares of common stock, 3,068,860 shares of common stock issuable upon conversion of one-third of the principal and accumulated interest of a $1,000,000 convertible promissory note and 8,240,593 common shares issuable upon the conversion of the Series B Convertible Preferred Stock issuable upon conversion of two convertible promissory notes in an aggregate principal amount of $1,121,000 and accumulated interest of $49,750.
|
8.
|
Consists of 1,765,388 shares of common stock and 14,667 shares subject to stock options. The exercise price of the stock options is 8,000 at $0.51 per share and 6,667 at $0.09 per share. Mr. Miller has sole or shared voting or dispositive power with respect to the securities held by Delphi Partners, Ltd., which holds 509,267 shares of common.
|
9.
|
Includes 556,179 shares of common stock and 1,333,333 common shares issuable upon conversion of the Series B Convertible Preferred Stock, warrants to acquire 333,333 shares of common stock and 9,667 shares subject to stock options. The exercise prices of the warrants are 333,333 at $0.25 per share. The exercise price of stock options is 5,000 at $0.51 per share and 4,667 at $0.09 per share.
|
10.
|
Includes 3,248 shares of common stock. 610,310 shares subject to stock options exercisable within sixty (60) days and 549,360 shares of restricted stock that is awarded upon resignation or termination and change of control. The exercise prices of stock options range from $0.09 to $39 per share of common stock.
|
11.
|
Includes 148,784 shares of common stock, and 100 shares of common stock held in a self-directed IRA and 14,667 shares subject to stock options. The exercise price of stock options is 8,000 at $0.51 per share and 6,667 at $0.09 per share of common stock.
|
12.
|
Consists of 32,652 shares of common stock and 15,667 shares subject to stock options. The exercise prices of stock options are as follows: 1,000 at $35.00 per share, 8,000 at $0.51 per share and 6,667 at $0.09 per share of common stock. Disclaims beneficial ownership of 1,000 shares of common stock because they are anti-dilutive.
|
13.
|
Consists of 80,286 shares of common stock and 14,667 shares subject to stock options. The exercise price of stock options is 8,000 at $0.51 per share and 6,667 at $0.09 per share of common stock.
|
14.
|
Consists of 50,000 shares subject to stock options. The exercise price of the stock options is $0.09 per share of common stock.
|
15.
|
Consists of 1,000 shares of common stock and 15,667 shares subject to stock options. The exercise prices of stock options are as follows: 1,000 at $34.00 per share, 8,000 at $0.51per share and 6,667 at $0.09 per share of common stock.
|
16.
|
Includes 193,934 shares of common stock and 1,000,000 common shares issuable upon conversion of the Series B Convertible Preferred Stock, warrants to acquire 250,000 shares of common stock. The exercise prices of the warrants are 250,000 at $0.25 per share.
|
17.
|
Includes shares issuable upon exercise of options and warrants exercisable within sixty (60) days as described in Notes 7-14 to our financial statements.
|
Exhibit Number |
|
Description
|
3.1
|
Certificate of Incorporation of Level 8 Systems, Inc., a Delaware corporation, as amended and restated December 29, 2006 (incorporated by reference to exhibit 3.1 to Level 8’s Form 8-K filed
January 17, 2007).
|
3.2
|
Certificate of Designation relating to Series A1 Convertible Redeemable Preferred Stock (incorporated by reference to exhibit 3.2 to Level 8’s Form 8-K filed January 17, 2007).
|
3.3
|
Certificate of Incorporation of Level 8 Systems, Inc., a Delaware corporation, as amended August 4, 2003 (incorporated by reference to exhibit 3.1 to Level 8’s Form 10-K filed March 31, 2004).
|
3.4
|
Bylaws of Level 8 Systems, Inc., a Delaware corporation (incorporated by reference to exhibit 3.2 to Level 8’s Form 10-K filed April 2, 2002).
|
3.5
|
Certificate of Designation relating to Series B Convertible Redeemable Preferred Stock (incorporated by reference to exhibit 3.1 to Level 8’s Form 8-K filed January 20, 2010).
|
4.1
|
Form of Long term Promissory Note Stock Purchase Warrant (incorporated by reference to exhibit 4.19 to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
4.2
|
Form of Long term Promissory Note Stock Purchase Warrant (incorporated by reference to exhibit 4.17 to Cicero Inc.’s Form 10-K filed March 31, 2009).
|
4.3
|
Form of Amended Long term Promissory Note Stock Purchase Warrant (incorporated by reference to exhibit 4.3 to Cicero Inc.’s Form 10-K filed March 31, 2011).
|
10.1
|
Securities Purchase Agreement for Consortium IV (incorporated by reference to exhibit 10.1 to Cicero Inc.’s Form 10-K/A filed July 11, 2007).
|
10.2
|
Amended PCA Shell License Agreement, dated as of January 3, 2002, between Level 8 Systems, Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated (incorporated by reference to exhibit 10.2 to Level 8's Form 8-K, filed January 11, 2002).
|
10.3A
|
PCA Shell License Agreement between Level 8 Systems, Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated (incorporated by reference to exhibit 10.2 to Level 8’s Report on Form 8-K, filed September 11, 2000).
|
10.3B
|
OEM License Agreement between Cicero Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated (incorporated by reference to exhibit 10.12A to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
10.3C
|
Software Support and Maintenance Schedule between Cicero Inc. and Merrill Lynch, Pierce, Fenner & Smith Incorporated (incorporated by reference to exhibit 10.12A to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
10.4
|
Employment Agreement between John P. Broderick and the Company effective January 1, 2011 (incorporated by reference to exhibit 10.16 to Cicero Inc.’s Form 10-K filed April 1, 2010). *
|
10.5
|
Lease Agreement for Cary, N.C. offices, dated November 7, 2003, between Level 8 Systems, Inc. and Regency Park Corporation (incorporated by reference to exhibit 10.17 to Level 8’s Form 10-K, filed March 31, 2004).
|
10.6
|
Level 8 Systems Inc. 1997 Stock Option Plan, as Amended and Restated (incorporated by reference to exhibit 10.2 to Level 8’s Registration Statement on Form S-1/A, filed September 22, 2000, File No. 333-44588).*
|
10.7A
|
Fifth Amendment to Level 8 Systems Inc. 1997 Stock Option Plan (incorporated by reference to exhibit 10.9A to Level 8’s Form 10-K filed April 2, 2002).*
|
10.8B
|
Seventh Amendment to Level 8 Systems Inc. 1997 Stock Option Plan (incorporated by reference to exhibit 10.14 B to Level 8’s Form 10-K, filed March 31, 2004).*
|
10.9
|
Lease Agreement for Cary, N.C. offices, dated August 16
,
2007, between Cicero Inc. and Regency Park Corporation (incorporated by reference to exhibit 10.21 to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
10.10
|
Cicero Inc. 2007 Employee Stock Option Plan (incorporated by reference to exhibit 10.22 to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
10.11
|
Agreement and Promissory Note of Cicero Inc., dated October 30, 2007 among Cicero Inc. and BluePhoenix Solutions Ltd. (incorporated by reference to exhibit 10.23 to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
10.12
|
Promissory Note of Cicero Inc., dated October 29, 2007 among Cicero Inc. and John L. Steffens (incorporated by reference to exhibit 10.24 to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
10.13
|
Securities Purchase Agreement, dated as of February 26, 2007, by and among Cicero Inc. and the Purchasers in the February Private Placement (incorporated by reference to exhibit 10.25 to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
10.14
|
Securities Purchase Agreement, dated as of August 15, 2007, by and among Cicero Inc. and the Purchasers in the August Private Placement (incorporated by reference to exhibit 10.26 to Cicero Inc.’s Form 10-K filed March 31, 2008).
|
10.15
|
Revolving Loan Agreement dated November 3, 2008 among Cicero Inc. and Barbara Sivan (incorporated by reference to exhibit 10.15 to Cicero Inc., Form 10-K filed March 31, 2009).
|
Employment Agreement between John P. Broderick and the Company effective January 1, 2012 (filed herewith).
|
10.17
|
Form of Long Term Promissory Note dated March 31, 2009 (incorporated by reference to exhibit 10.17 to Cicero Inc., Form 10-K filed March 31, 2009).
|
Employment Agreement between Antony Castagno and the Company effective January 1, 2012 (filed herewith).*
|
10.19
|
Asset Purchase Agreement dated January 15, 2010 between Cicero Inc., Vertical Thought Inc., and SOAdesk LLC (incorporated by reference to exhibit 2.1 to Cicero’s Form 8-K filed January 20, 2010).
|
10.20
|
Amendment No. 1 to the Purchase Agreement dated January 15, 2010 between Cicero Inc., Vertical Thought Inc., and SOADesk LLC (incorporated by reference to exhibit 2.1 to Cicero’s Form 8-K/A filed April 2, 2010).
|
10.21
|
Registration Rights Agreement, dated as of January 15, 2010, by and among Cicero Inc. and the Purchasers thereto (incorporated by reference to exhibit 4.4 to Cicero Inc.’s Form 8-K filed January 20, 2010)
|
10.22
|
Employment Agreement between Antony Castagno and the Company effective January 1, 2011 (incorporated by reference to exhibit 10.16 to Cicero Inc.’s Form 10-K filed April 1, 2010).*
|
Source Code License Agreement between Cicero Inc. and Convergys Customer Management Group Inc. (filed herewith).
|
10.9
|
Lease Agreement for Cary, N.C. offices, dated July 21,
2010, between Cicero Inc. and Regency Park Corporation (incorporated by reference to exhibit 10.9 to Cicero Inc.’s Form 10-K filed March 31, 2011).
|
Form of Short Term Promissory Note of Cicero Inc. among Cicero Inc. and John L. Steffens (filed herewith).
|
14.1
|
Code of Ethics (incorporated by reference to exhibit 14.1 to Level 8’s Form 10-K/A, filed
March 31, 2004).
|
List of subsidiaries of the Company (filed herewith).
|
Consent of Marcum LLP (filed herewith).
|
Certification of Chief Executive pursuant to Rule 13a-14(a) (filed herewith).
|
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) (filed herewith).
|
Certification of John P. Broderick pursuant to 18 USC § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002 (filed herewith).
|
CICERO INC. | |||
Date: April 16, 2012
|
By:
|
/s/ John P. Broderick | |
John P. Broderick | |||
Chief Executive Officer and Chief Financial Officer | |||
Signature
|
Title
|
Date
|
||
/
s/John L. Steffens
|
Chairman of the Board
|
April 16, 2012
|
||
John L. Steffens | ||||
/s/ John P. Broderick
|
Chief Executive Officer/Chief Financial Officer
(Principal Executive Officer)
|
April 16, 2012
|
||
John P. Broderick | ||||
/s/ Antony Castagno
|
Chief Technology Officer
|
April 16, 2012
|
||
Antony Castagno | ||||
/s/ Mark Landis
|
Director
|
April 16, 2012
|
||
Mark Landis | ||||
/s/ Bruce Hasenyager
|
Director
|
April 16, 2012
|
||
Bruce Hasenyager | ||||
/s/ Jay Kingley
|
Director
|
April 16, 2012
|
||
Jay Kingley | ||||
/s/ Bruce D. Miller
|
Director
|
April 16, 2012
|
||
Bruce D. Miller | ||||
/s/ Charles Porciello
|
Director
|
April 16, 2012
|
||
Charles Porciello | ||||
/s/ John W. Atherton
|
Director
|
April 16, 2012
|
||
John W. Atherton | ||||
/s/ Don Peppers
|
Director
|
April 16, 2012
|
||
Don Peppers |
Report of Independent Registered Public Accounting Firm for the years ended
December 31, 2011 and 2010
|
F-2 | |||
Financial Statements:
|
||||
Consolidated Balance Sheets | F-3 | |||
Consolidated Statements of Operations | F-4 | |||
Consolidated Statements of Stockholders' Deficit | F-5 | |||
Consolidated Statements of Cash Flows | F-6 | |||
Notes to Consolidated Financial Statements | F-8 |
December 31,
2011
|
December 31,
2010
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash
|
$ | 184 | $ | 43 | ||||
Trade accounts receivable, net
|
861 | 137 | ||||||
Prepaid expenses and other current assets
|
404 | 279 | ||||||
Total current assets
|
1,449 | 459 | ||||||
Property and equipment, net
|
32 | 40 | ||||||
Intangible asset, net (Note 6)
|
729 | 1,430 | ||||||
Goodwill (Note 6)
|
2,832 | 2,832 | ||||||
Total assets
|
$ | 5,042 | $ | 4,761 | ||||
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
||||||||
Current liabilities:
|
||||||||
Short-term debt (Note 7)
|
$ | 6,137 | $ | 1,473 | ||||
Accounts payable
|
3,170 | 1,357 | ||||||
Accrued expenses:
|
||||||||
Salaries, wages, and related items
|
1,407 | 1,251 | ||||||
Earn-out contingency (Note 3)
|
-- | 789 | ||||||
Other
|
424 | 1,741 | ||||||
Deferred revenue (Note 2)
|
1,611 | 374 | ||||||
Total current liabilities
|
12,749 | 6,985 | ||||||
Long-term debt (Note 8)
|
1,916 | 4,440 | ||||||
Total liabilities
|
14,665 | 11,425 | ||||||
Commitments and contingencies (Notes 15 and 16)
|
||||||||
Stockholders' deficit:
|
||||||||
Convertible preferred stock, $0.001 par value, 10,000,000 shares authorized
Series A-1 – 1,542.6 shares issued and outstanding at December 31, 2011 and 1,543.6 shares issued and outstanding at December 31, 2010, $500 per share liquidation preference (aggregate liquidation value of $772)
|
-- | -- | ||||||
Series B – 10,400 shares issued and outstanding at December 31, 2011 and 2010, $500 per share liquidation preference (aggregate liquidation value of $5,200)
|
-- | -- | ||||||
Common stock, $0.001 par value, 215,000,000 shares authorized at December 31, 2011 and 2010, respectively; 47,444,524 issued and outstanding at December 31, 2011 and 47,098,185 issued and outstanding at December 31, 2010 (Note 10)
|
47 | 47 | ||||||
Additional paid-in-capital
|
232,506 | 232,369 | ||||||
Accumulated deficit
|
(242,176 | ) | (239,080 | ) | ||||
Total stockholders' deficit
|
(9,623 | ) | (6,664 | ) | ||||
Total liabilities and stockholders' deficit
|
$ | 5,042 | $ | 4,761 |
Years Ended December 31,
|
||||||||
2011
|
2010
|
|||||||
Revenue:
|
||||||||
Software
|
$ | 676 | $ | 1,086 | ||||
Maintenance
|
1,540 | 1,427 | ||||||
Services
|
1,038 | 463 | ||||||
Total operating revenue
|
3,254 | 2,976 | ||||||
Cost of revenue:
|
||||||||
Software
|
701 | 672 | ||||||
Maintenance
|
114 | 146 | ||||||
Services
|
1,062 | 912 | ||||||
Total cost of revenue
|
1,877 | 1,730 | ||||||
Gross margin
|
1,377 | 1,246 | ||||||
Operating expenses:
|
||||||||
Sales and marketing
|
1,893 | 1,978 | ||||||
Research and product development
|
969 | 876 | ||||||
General and administrative
|
1,189 | 1,260 | ||||||
Total operating expenses
|
4,051 | 4,114 | ||||||
Loss from continuing operations before other income (charges)
|
(2,674 | ) | (2,868 | ) | ||||
Other income (charges):
|
||||||||
Interest expense
|
(813 | ) | (740 | ) | ||||
Other (Note 1)
|
517 | 3,149 | ||||||
(296 | ) | 2,409 | ||||||
Net loss
|
(2,970 | ) | (459 | ) | ||||
Deemed dividend on preferred stock and
8% preferred stock Series B dividend
|
126 | 184 | ||||||
Net loss applicable to common stockholders
|
$ | (3,096 | ) | $ | (643 | ) | ||
Loss per share – basic and diluted
|
$ | (0.07 | ) | $ | (0.01 | ) | ||
Average shares outstanding – basic and diluted
|
47,341 | 47,098 |
Common Stock
|
Preferred Stock
|
Additional
Paid-in
|
Accumulated
|
|||||||||||||||||||||||||
Shares | Amount | Shares | Amount |
Capital
|
(Deficit)
|
Total
|
||||||||||||||||||||||
Balance at December 31, 2009
|
47,098 | 47 | 2 | -- | $ | 230,464 | $ | (238,437 | ) | $ | (7,926 | ) | ||||||||||||||||
Issuance of preferred B stock for cash
|
4 | 700 | 700 | |||||||||||||||||||||||||
Issuance of preferred B stock for loan conversion
|
6 | 860 | 860 | |||||||||||||||||||||||||
Dividend for preferred B stock
|
(117 | ) | (117 | ) | ||||||||||||||||||||||||
Deemed dividend
|
67 | (67 | ) | -- | ||||||||||||||||||||||||
Beneficial conversion of preferred B stock
|
175 | 175 | ||||||||||||||||||||||||||
Options issued as compensation
|
67 | 67 | ||||||||||||||||||||||||||
Restricted shares issued as compensation
|
36 | 36 | ||||||||||||||||||||||||||
Net loss
|
(459 | ) | (459 | ) | ||||||||||||||||||||||||
Balance at December 31, 2010
|
47,098 | $ | 47 | 12 | -- | $ | 232,369 | $ | (239,080 | ) | $ | (6,664 | ) | |||||||||||||||
Dividend for preferred B stock
|
(126 | ) | (126 | ) | ||||||||||||||||||||||||
Beneficial conversion of preferred A stock
|
1 | -- | ||||||||||||||||||||||||||
Issuance of stock for payment of interest
|
345 | 26 | 26 | |||||||||||||||||||||||||
Options issued as compensation
|
75 | 75 | ||||||||||||||||||||||||||
Restricted shares issued as compensation
|
36 | 36 | ||||||||||||||||||||||||||
Net loss
|
(2,970 | ) | (2,970 | ) | ||||||||||||||||||||||||
Balance at December 31, 2011
|
47,444 | $ | 47 | 12 | -- | $ | 232,506 | $ | (242,176 | ) | $ | (9,623 | ) |
Years Ended December 31,
|
||||||||
2011
|
2010
|
|||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$ | (2,970 | ) | $ | (459 | ) | ||
Adjustments to reconcile net loss to net cash (used in) operating activities:
|
||||||||
Depreciation and amortization
|
722 | 694 | ||||||
Stock compensation expense
|
111 | 103 | ||||||
Bad debt expense
|
14 | -- | ||||||
Amortization of debt discount
|
-- | 175 | ||||||
Gain on write off of liabilities
|
-- | (2,010 | ) | |||||
Gain on write down of earn out contingency
|
(517 | ) | (1,050 | ) | ||||
Changes in assets and liabilities:
|
||||||||
Trade accounts receivable and related party receivables
|
(738 | ) | 88 | |||||
Prepaid expenses and other assets
|
(125 | ) | 66 | |||||
Accounts payable and accrued expenses
|
1,063 | 586 | ||||||
Deferred revenue
|
1,237 | 131 | ||||||
Net cash used in operating activities
|
(1,203 | ) | (1,676 | ) | ||||
Cash flows from investing activities:
|
||||||||
Purchases of property and equipment
|
(13 | ) | (22 | ) | ||||
Cash Paid for Acquisition of SOAdesk assets
|
-- | (300 | ) | |||||
Net cash used in investing activities
|
(13 | ) | (322 | ) | ||||
Cash flows from financing activities:
|
||||||||
Issuance of Series B convertible preferred stock
|
-- | 700 | ||||||
Borrowings under short and long-term debt
|
2,021 | 2,116 | ||||||
Repayments of short and long-term debt
|
(664 | ) | (787 | ) | ||||
Net cash provided by financing activities
|
1,357 | 2,029 | ||||||
Net increase in cash
|
141 | 31 | ||||||
Cash at beginning of year
|
43 | 12 | ||||||
Cash at end of year
|
$ | 184 | $ | 43 | ||||
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
|
||||||||
Cash paid during the year for:
|
||||||||
Income taxes
|
$ | 21 | $ | 10 | ||||
Interest
|
$ | 225 | $ | 198 |
NOTE 1.
|
SUMMARY OF OPERATIONS, SIGNIFICANT ACCOUNTING POLICIES AND RECENT ACCOUNTING PRONOUNCEMENTS
|
December 31,
|
||||||||
2011
|
2010
|
|||||||
Fair Value
|
$ | 1,887,709 | $ | 4,244,579 | ||||
Carrying Value
|
$ | 1,916,000 | $ | 4,440,000 |
2011
|
2010
|
|||||||
Stock options
|
4,296,193 | 3,503,157 | ||||||
Warrants
|
3,888,285 | 3,989,400 | ||||||
Preferred stock
|
11,942,618 | 11,943,618 | ||||||
20,127,096 | 19,436,175 |
2011
|
2010
|
|||||||
Fair value of common stock
|
$ | 0.07 | $ | 0.09 | ||||
Expected life (in years)
|
10.0 years
|
10.0 years
|
||||||
Expected volatility
|
140 | % | 158 | % | ||||
Risk free interest rate
|
0.12 | % | 0.19 | % | ||||
Expected dividend yield
|
0 | % | 0 | % |
Consideration:
|
||||
Cash paid
|
$ | 300,000 | ||
Cnvertible notes payable
|
2,225,000 | |||
Earn-out contingency
|
2,410,000 | |||
Total Consideration
|
$ | 4,935,000 | ||
Allocated to:
|
||||
Software
|
$ | 2,103,000 | ||
Goodwill ($141,000 is expected to be deductible for tax purposes)
|
$ | 2,832,000 | ||
$ | 4,935,000 |
2011
|
2010
|
|||||||
Current trade accounts receivable
|
$ | 861 | $ | 137 |
2011
|
2010
|
|||||||
Computer equipment
|
$ | 322 | $ | 310 | ||||
Furniture and fixtures
|
24 | 24 | ||||||
Office equipment
|
169 | 169 | ||||||
515 | 503 | |||||||
Less: accumulated depreciation and amortization
|
(483 | ) | (463 | ) | ||||
$ | 32 | $ | 40 |
2011
|
2010
|
|||||||
Term loan (a)
|
$ | 753 | $ | 671 | ||||
Note payable asset purchase agreement (b)
|
1,121 | -- | ||||||
Note payable related parties (c)
|
2,959 | 9 | ||||||
Notes payable (d)
|
1,304 | 793 | ||||||
$ | 6,137 | $ | 1,473 |
(a)
|
In October 2007, the Company agreed to restructure the note payable to Bank Hapoalim and guaranty by BluePhoenix Solutions. Under a new agreement with BluePhoenix, the Company made a principal reduction payment to Bank Hapoalim in the amount of $300,000. Simultaneously, BluePhoenix paid $1,671,000 to Bank Hapoalim, thereby discharging that indebtedness. The Company and BluePhoenix entered into a new note in the amount of $1,021,000, bearing interest at LIBOR plus 1.0% and maturing on December 31, 2011. In addition, BluePhoenix acquired 2,546,149 shares of the Company’s common stock in exchange for $650,000 paid to Bank Hapoalim to retire that indebtedness. Of the new note payable to BluePhoenix, approximately $350,000 was due on January 31, 2009 and the balance was due on December 31, 2011. During 2008, the Company paid $200,000 against the principal and BluePhoenix converted $50,000 of principal into 195,848 shares of Cicero common stock. In January 2009, the Company paid $100,000 against the principal. In January 2012, the Company entered into an addendum to the original note to extend the maturity of all outstanding principal and interest of $752,594 to December 31, 2012. At the time of the extension, the Company paid $150,000 towards principal and interest on this note. The unpaid principal and accumulated interest shall bear interest at a rate of LIBOR (3 months $ LIBOR, 0.518%) plus 6.7% per annum calculated quarterly. In March 2012, the Company made a $50,000 principal reduction payment. In April 2012, the Company paid the note at a discount in the amount of $380,000 and recognized approximately $170,000 as a gain.
|
(b)
|
At December 31, 2011, the Company was indebted to SOAdesk LLC for the remaining portion of the related long term debt of $1,121,000. (See Note 8)
|
|
(c)
|
From time to time during 2010 and 2011, the Company entered into several short term notes payable with John L. (Launny) Steffens, the Chairman of the Board of Directors, for various working capital needs. The notes bear interest at 12% per year and are unsecured. At December 31, 2011, the Company was indebted to Mr. Steffens in the amount of $3,065,000 of which $1,665,000 was reclassified from long term debt. (See Note 8) In March 2012, Mr. Steffens converted $3,000,000 of his debt, which included $350,000 which was lent to the Company in the first quarter of 2012, into 20,000,000 shares of common stock of the Company. In March 2012, Mr. Steffens agreed to refinance $115,000 of debt and $417,000 of accrued interest at an interest rate of 12% and a maturity date of March 31, 2013. As such this amount has been reclassified to long term debt. (See Note 8)
From time to time the Company entered into promissory notes with one of the Company’s former directors and the former Chief Information Officer, Anthony Pizi. The notes bear interest at 12% per annum. As of December 31, 2011 and 2010, the Company was indebted to Anthony Pizi in the amount of $9,000. In March 2012, Mr. Pizi converted his indebtedness into 171,487 shares of common stock of the Company.
|
(d)
|
The Company has issued a series of short term promissory notes with private lenders, which provide for short term borrowings, both secured by accounts receivable and unsecured. The notes in the amount of $718,000 bear interest between 10% and 36% per annum. In March 2012, the Company converted $235,000 of these notes into 1,566,667 shares of Company’s Common Stock. In March 2012, certain private lenders agreed to refinance $83,000 of debt and $301,000 of accrued interest at an interest rate of 12% and a maturity date of March 31, 2013. As such this amount has been reclassified to long term debt. (See Note 8).
At December 31, 2011, the Company was indebted for the remaining portion of the related long term debt for several secured Promissory Notes with certain investors in the aggregate amount of $650,000 that were secured by the amount due under the Company’s support contract with Merrill Lynch. (See Note 8) In March 2012, these notes were paid in full.
In August 2011, the Company entered into a promissory note with an employee for various working capital needs. The note bears interest at 6% per year and is unsecured. As of December 31, 2011, the Company was indebted to this employee in the amount of $19,000.
|
2011
|
2010
|
|||||||
Note payable – asset purchase agreement (a)
|
$ | -- | $ | 1,125 | ||||
Note payable – related party (b)
|
532 | 1,665 | ||||||
Other long-term debt (c)
|
1,384 | 1,650 | ||||||
$ | 1,916 | $ | 4,440 |
(a)
|
In January 2010, per the Asset Purchase Agreement, the Company entered into an unsecured convertible promissory note with SOAdesk for $700,000 with an annual interest rate of 5%. The note was originally scheduled to mature on March 31, 2010 but was subsequently amended to extend the maturity date to September 30, 2010 and was secured with shares of the Company’s Series B Preferred Stock. As of September 30, 2010, the maturity date was extended to March 31, 2011. In March 2011, the Company and SOAdesk LLC agreed to extend the maturity on the note to March 31, 2012. At December 31, 2011 and 2010, the Company was indebted to SOAdesk in the amount of $700,000 of which the amount at December 31, 2011, has been reclassified to short term debt (See Note 7). In March 2012, the Company and SOAdesk LLC agreed to extend the maturity on the note to December 31, 2012.
The note is convertible into shares of Series B Convertible Preferred Stock at the rate of one share per every $150 of principal and interest due under the note. The Company is obligated to repay any principal of the loan with fifty percent of any gross proceeds of any Series B Preferred capital raise through maturity of the note. The note is convertible at the holder’s option at any time or at maturity
.
Also, as part of the Asset Purchase Agreement, the Company was to pay to the shareholders of SOAdesk LLC the sum of $525,000 on March 31, 2010. In March 2010, the terms of the Asset Purchase Agreement were amended and the Company issued a $525,000 convertible promissory note to SOAdesk in lieu of the $525,000 payment originally due on March 31, 2010. This note, which carries an annual interest rate of 5%, is secured by shares of the Company’s Series B Preferred Stock. The note was to mature on June 30, 2010 but was subsequently amended to extend the maturity date to September 30, 2010. As of September 30, 2010, the maturity date was further extended to March 31, 2011. In March 2011, the Company and SOAdesk LLC agreed to extend the maturity on the note until March 31, 2012. In March 2012, the Company and SOAdesk LLC agreed to extend the maturity on the note until December 31, 2012. In April 2010 and May 2011, the Company paid $100,000 and $4,000, respectively, against the principal resulting in the balance SOAdesk due of $421,000 and $425,000 at December 31, 2011 and 2010, respectively, the balance of which was reclassified to short term debt (See Note 7). In April 2012, the note was paid in full.
The note is convertible into shares of Series B Convertible Preferred Stock at the rate of one share per every $150 of principal and interest due under the note. The Company is obligated to repay any principal of the loan with fifty percent of any gross proceeds of any Series B Preferred capital raise through maturity of the note. The note is convertible into Series B Preferred Stock at the holder’s option at any time or at maturity.
In accordance with ASC 470-20 “Debt with Conversion and Other Options”, the Company has determined the embedded conversion option is beneficial and has intrinsic value to the holder. The total debt discount to be recognized is $175,000 and the Company has reduced the note by that amount and increased Additional Paid in Capital by the same amount. As of December 31, 2010, the Company had amortized $175,000 in the statement of operations.
|
(b)
|
From time to time during 2010, the Company entered into several short term notes payable with John L. (Launny) Steffens, the Chairman of the Board of Directors, for various working capital needs. The notes bear interest at 12% per year and are unsecured. At December 31, 2010, the Company was indebted to Mr. Steffens in the amount of $1,665,000. In March 2011, the Company and Mr. Steffens agreed to extend the maturity on the notes until March 31, 2012. At December 31, 2011, the balance was reclassified to short term debt. (See Note 7) In March 2012, Mr. Steffens agreed to refinance $115,000 of debt and $417,000 of accrued interest at an interest rate of 12% and a maturity date of March 31, 2013. As such this amount has been reclassified to long term debt. (See Note 7)
|
(c)
|
In March 2009, the Company entered into several secured Promissory Notes with certain investors in the aggregate amount of $750,000. The notes bear interest at 15% and mature on January 31, 2012. The notes are secured by the amount due under the Company’s support contract with Merrill Lynch. In addition, each investor was issued a warrant to purchase common stock of the Company. Under the terms of the warrant, which expires in five years, each note holder is entitled to purchase 1,000 shares of Cicero common stock for every $1,000 of principal due under the note. The exercise price on the warrant is $0.20 per share. The shares of common stock underlying the warrants have registration rights and a cashless exercise provision in the event no registration statement is effective for resale, if required. The Company has allocated the proceeds received from the Note and Warrant Offering based on relative fair value and is amortizing such amount under the terms of the notes as additional interest expense in the amount of $50,349. In February 2010, the Company reduced the principal indebtedness by $100,000. At December 31, 2011 and 2010, the Company was indebted to these investors in the amount of $650,000 of which the amount at December 31, 2011 has been reclassified to short term debt. (See Note 7) In March 2012, these notes were paid in full.
In January 2010, as part of the Asset Purchase Agreement, the Company entered into an unsecured Convertible Promissory Note with SOAdesk in the amount of $1,000,000. The note bears interest at 5% and is due November 14, 2015. The note is only convertible into shares of the Company’s common stock at the rate of one share for every $0.15 of principal and interest due under the note. The note is convertible at the option of the holder with one-third convertible in January 2011, two-thirds convertible in January 2012, and the entire note convertible in January 2013 or at maturity. In March 2012, SOAdesk elected to convert $300,000 of the outstanding note balance into 2,000,000 shares of Company’s Common Stock.
In March 2012, certain private lenders agreed to refinance $83,000 of debt and $301,000 of accrued interest at an interest rate of 12% and a maturity date of March 31, 2013. As such this amount has been reclassified to long term debt. (See Note 7)
|
Year
|
||||
2013 | $ | 916,000 | ||
2015
|
$ | 1,000,000 | ||
$ | 1,916,000 |
2011
|
2010
|
|||||||
Expected income tax benefit at statutory rate (34%)
|
$ | (1,010 | ) | $ | (156 | ) | ||
State taxes, net of federal tax benefit.
|
(176 | ) | (27 | ) | ||||
Effect of change in valuation allowance
|
(15,568 | ) | (125 | ) | ||||
Non-deductible expenses
|
12 | 6 | ||||||
Expiration of net operating loss deductions
|
16,742 | 302 | ||||||
Total
|
$ | -- | $ | -- |
2011
|
2010
|
|||||||
Current assets:
|
||||||||
Accrued expenses, non-tax deductible
|
$ | 344 | $ | 296 | ||||
Deferred revenue
|
645 | 149 | ||||||
Contingent payments
|
(627 | ) | (420 | ) | ||||
Noncurrent assets:
|
||||||||
Stock compensation expense
|
513 | 469 | ||||||
Loss carryforwards
|
79,811 | 95,211 | ||||||
Depreciation and amortization
|
2,486 | 3,035 | ||||||
83,172 | 98,740 | |||||||
Less: valuation allowance
|
(83,172 | ) | (98,740 | ) | ||||
$ | -- | $ | -- |
Number of
Options
|
Option Price
Per Share
|
Weighted Average
Exercise Price
|
Aggregate
Intrinsic Value
|
|||||||||||||
Balance at December 31, 2009
|
2,707,006 | 0.10-3,931.25 | $ | 1.10 | ||||||||||||
Granted
|
1,444,750 | 0.09 | $ | 0.09 | ||||||||||||
Forfeited
|
(648,599 | ) | 0.09-3,931.25 | $ | 1.21 | |||||||||||
Balance at December 31, 2010
|
3,503,157 | 0.09-581.00 | $ | 0.60 | ||||||||||||
Granted
|
880,000 | 0.06-0.10 | $ | 0.07 | ||||||||||||
Forfeited
|
(85,000 | ) | 0.09-0.10 | $ | 0.10 | |||||||||||
Expired
|
(1,964 | ) | 174.00-581.00 | $ | 234.78 | |||||||||||
Balance at December 31, 2011
|
4,296,193 | 0.06-39.00 | $ | 0.39 | $ | 0.00 |
Number of
Options
|
Option Price
Per Share
|
Weighted Average
Exercise Price
|
||||||||||
Balance at December 31, 2009
|
338,334
|
0.10-0.25 | $ | 0.15 | ||||||||
Granted
|
1,444,750 | 0.09 | $ | 0.09 | ||||||||
Vested
|
(669,915 | ) | 0.09-0.25 | $ | 0.11 | |||||||
Forfeited
|
(91,666 | ) | 0.09-0.25 | $ | 0.16 | |||||||
Balance at December 31, 2010
|
1,021,503 | 0.09 | $ | 0.09 | ||||||||
Granted
|
880,000 | 0.06-0.10 | $ | 0.07 | ||||||||
Vested
|
(945,756 | ) | 0.06-0.15 | $ | 0.08 | |||||||
Forfeited
|
(3,333 | ) | 0.09 | $ | 0.09 | |||||||
Balance at December 31, 2011
|
952,414 | 0.06-0.10 | $ | 0.08 |
EXERCISE PRICE
|
NUMBER
OUTSTANDING
|
REMAINING
CONTRACTUAL
LIFE FOR OPTIONS
OUTSTANDING
|
NUMBER
EXERCISABLE
|
WEIGHTED
AVERAGE
EXERCISE
PRICE
|
||||||||||||||
$ | 0.06-0.08 | 892,500 | 9.6 | 410,000 | $ | 0.07 | ||||||||||||
0.09 | 1,359,750 | 8.6 | 906,503 | 0.09 | ||||||||||||||
0.10-0.37 | 390,000 | 7.1 | 373,333 | 0.15 | ||||||||||||||
0.38-46.00 | 1,653,943 | 5.58 | 1,653,943 | 0.88 | ||||||||||||||
4,296,193 | 7.5 | 3,343,779 | $ | 0.48 |
Expected
Life in
Years
|
Expected
Volatility
|
Risk Free
Interest
Rate
|
Expected
Dividend
|
Fair Value
of Common
Stock
|
Number of
Outstanding
Warrants
|
|||||||||||||||||||
Series B Preferred Stock Warrants
|
5 | 118 | % | 3.96 | % | 8 | % | $ | 0.25 | 2,600,000 | ||||||||||||||
SOAdesk Loan Extension Warrants
|
5 | 100 | % | 2.20 | % | -- | $ | 0.08 | 100,000 |
Lease
Commitments
|
||||
2012
|
$ | 95 | ||
2013
|
98 | |||
2014
|
59 | |||
$ | 252 |
1.
|
Employment
. The Company hereby employs Employee and Employee hereby accepts such employment upon the terms and conditions set forth in this Agreement.
|
2.
|
Duties of Employee
. Employee will be based in New Jersey or North Carolina at the discretion of the Company. Employee’s title will be Chief Executive Officer, Chief Financial Officer, Chief Operating Officer and Corporate Secretary and Employee will report directly to the Board of Directors of the Company. Employee agrees to perform and discharge such other duties as may be assigned to Employee from time to time by the Company to the reasonable satisfaction of the Board of Directors , and such duties will be consistent with those duties regularly and customarily assigned by the Company to the position of Chief Executive Officer, Chief Financial Officer and Secretary. Employee agrees to comply with all of the Company's policies, standards and regulations and to follow the instructions and directives as promulgated by the Board of Directors of the Company. Employee will devote Employee's full professional and business-related time, skills and best efforts to such duties and will not, during the term of this Agreement, be engaged (whether or not during normal business hours) in any other business or professional activity, whether or not such activity is pursued for gain, profit or other pecuniary advantage, without the prior written consent of the Board of Directors of the Company. This Section will not be construed to prevent Employee from (a) investing personal assets in businesses which do not compete with the Company in such form or manner that will not require any services on the part of Employee in the operation or the affairs of the companies in which such investments are made and in which Employee's participation is solely that of an investor; (b) purchasing securities in any corporation whose securities are listed on a national securities exchange or regularly traded in the over-the-counter market, provided that Employee at no time owns, directly or indirectly, in excess of one percent (1%) of the outstanding stock of any class of any such corporation engaged in a business competitive with that of the Company; or (c) participating in conferences, preparing and publishing papers or books, teaching or joining or participating in any professional associations or trade group, so long as the Board of Directors of the Company approves such participation, preparation and publication or teaching prior to Employee’s engaging therein.
|
3.
|
Term
. The term of this Agreement will be at-will, and can be terminated by either party at any time, with or without cause, subject to the provisions of Section 4 of this Agreement. Subject to the provisions of Section4, this Agreement will cover the period January 1, 2012 through December 31, 2012 and thereafter successive annual periods unless a party provides the other with written notice of its intention to terminate this Agreement, which notice shall be delivered no later than thirty (30) days prior to the expiration of the initial term or any renewal term, as applicable.
|
4.
|
Termination
.
|
|
(a)
|
Termination by Company for Cause
. The Company may terminate this Agreement and all of its obligations hereunder immediately, including the obligation to pay Employee severance, vacation pay or any further accrued benefits or remuneration, if any of the following events occur:
|
|
(i)
|
Employee improperly performs, or fails to perform, his duties and responsibilities or materially breaches any of the terms or conditions set forth in this Agreement, a Policy, or invention assignment, confidentiality, non-solicitation or non-competition agreement with or for the benefit of the Company, and fails to cure such breach within ten (10) days after Employee's receipt from the Company of written notice of such breach (notwithstanding the foregoing, no cure period shall be applicable to breaches by Employee of Sections 10 through 14 of this Agreement or of provisions of such Policies or agreements relating to any thereof);
|
|
(ii)
|
Employee commits any other act materially detrimental to the business or reputation of the Company;
|
|
(iii)
|
Employee engages in willful misconduct, including fraud or intentional misrepresentation;
|
|
(iv)
|
Employee engages in dishonest activities or commits or is convicted of, or pleads guilty or nolo contendere to, any felony or a misdemeanor involving fraud, deceit, moral turpitude or unethical business conduct;
|
|
(v)
|
Employee engages in habitual alcohol or drug abuse that continues after written notice from the Company, which abuse has (a) had an adverse effect on Employee’s productivity or ability to carry out his duties under this Agreement, (b) jeopardized the safety of any other employee of the Company or any person having business relations with the Company, (c) damaged the reputation of the Company, or (d) endangered the Company’s ability to compete for business; or
|
|
(vi)
|
Employee dies or becomes mentally or physically incapacitated or disabled so as to be unable to perform Employee's duties under this Agreement even with a reasonable accommodation. Without limiting the generality of the foregoing, Employee's inability adequately to perform services under this Agreement for a period of sixty (60) consecutive days will be conclusive evidence of such mental or physical incapacity or disability, unless such inability is pursuant to a mental or physical incapacity or disability covered by the Family Medical Leave Act, in which case such sixty (60) day period shall be extended to a one hundred and twenty (120) day period.
|
|
(b)
|
Termination by Company Without Cause
. The Company may terminate Employee's employment pursuant to this Agreement for reasons other than those stated in Section 4(a) upon at least thirty (30) days' prior written notice to Employee. In the event Employee's employment with the Company is terminated by the Company without cause, the Company shall be obligated to pay Employee a lump sum severance payment equal to twelve (12) months of Employee’s then base salary payable within thirty (30) days after the date of termination. In addition, Employee will be entitled to payment of all unused vacation days at his current daily rate and any accrued but unpaid salary or earned bonuses. Any option grants or restricted stock awards made to employee will immediately vest. The payment to Employee for all deferred salaries and earned bonuses will be paid within 30 days by the Company. Other than the severance payments set forth in this Section 4(b), Employee will be entitled to receive no further remuneration and will not be entitled to participate in any Company benefit programs following his termination by the Company, whether such termination is with or without cause.
|
|
(c)
|
Termination by Employee for Cause
. In the event of a Change of Control (as defined below) of the Company that results in either a substantial reduction or change of title in the Employee’s job duties related to his position as CFO or CEO, ,or a decrease in or a failure to provide the compensation or vested benefits under this Agreement or the Company initiates a substantial reduction or change of title in the Employee’s job duties related to his position as CFO, Employee shall have the right to resign his employment and will be entitled to a lump sum severance payment equal to twelve (12) months of Employee’s then base salary payable within thirty (30) days after the date of termination In addition, Employee will be entitled to payment of all unused vacation days at his current daily rate and a lump sum equal to all deferred salaries and earned bonuses. In addition, all Employee’s then outstanding but unvested stock options shall vest one hundred percent (100%). Employee shall have 12 months from the date written notice is given to Employee about the announcement and closing of a transaction resulting in a Change in Control of the Company that would result in a substantial change in the Employee’s job duties or decrease his compensation or vested benefits under this Agreement to resign or this Section 4(c) shall not apply. In the event Employee resigns from the Company for any other reason, Employee will not be entitled to receive or accrue any further Company benefits or other remuneration under this Agreement, and Employee specifically agrees that he will not be entitled to receive any severance pay.
For purposes of this Section 4, a Change in Control shall be deemed to have occurred if any of the following occur:
|
|
(i)
|
the merger or consolidation of the Company with or into another unaffiliated entity, or the merger of another unaffiliated entity into the Company or another subsidiary thereof with the effect that immediately after such transaction the stockholders of the Company immediately prior to such transaction hold less than fifty percent (50%) of the total voting power of all securities generally entitled to vote in the election of directors, managers or trustees of the entity surviving such merger or consolidation. This provision will not apply to any reorganization and reverse merger between the Company and any subsidiary (or any other similar entity established for a similar purpose);
|
|
(ii)
|
the sale or transfer of more than fifty-one percent (51%) of the Company’s then outstanding voting stock (other than a restructuring event which results in the continuation of the Company’s business by an affiliated entity) to unaffiliated person or group (as such term is used in Section 13(d)(3) of the Securities Exchange Act of 1934, as amended); or
|
|
(iii)
|
the adoption by the stockholders of the Company of a plan relating to the liquidation or dissolution of the Company.
|
|
(a)
|
Annual Salary
. During the term of this Agreement and for all services rendered by Employee under this Agreement, the Company will pay Employee a base salary of One Hundred and Seventy-Five Thousand Dollars ($175,000.00) per annum in equal bi-monthly installments. Employee will also be entitled to earn a short term incentive compensation as further outlined in Exhibit D.
|
|
(b)
|
Incentive Compensation
. Employee is eligible for an annual bonus upon the Company reaching certain pre tax income levels (after accounting for all bonuses) as set forth in Exhibit C. Said bonus will be payable after the annual accounts have been presented to the Compensation Committee. Exhibit C attached hereto provides the benchmarks associated with achieving the Incentive Compensation.
|
|
(c)
|
Equity Awards
. Employee is eligible for stock option grants and restricted stock awards as determined by the Compensation Committee.
|
6.
|
Vacation.
Employee shall be eligible for four (4) weeks of paid vacation annually, provided that such vacation is scheduled at such times that do not interfere with the Company’s legitimate business needs.
|
7.
|
Other Benefits
. Employee will be entitled to such fringe benefits as may be provided from time-to-time by the Company to its employees, including, but not limited to, group health insurance, life and disability insurance, and any other fringe benefits now or hereafter provided by the Company to its employees, if and when Employee meets the eligibility requirements for any such benefit. The Company reserves the right to change or discontinue any employee benefit plans or programs now being offered to its employees; provided, however, that all benefits provided for employees of the same position and status as Employee will be provided to Employee on an equal basis.
|
8.
|
Business Expenses
. Employee will be reimbursed for all reasonable expenses incurred in the discharge of Employee's duties under this Agreement pursuant to the Company's standard reimbursement policies.
|
9.
|
Withholding
. The Company will deduct and withhold from the payments made to Employee under this Agreement, state and federal income taxes, FICA and other amounts normally withheld from compensation due employees.
|
10.
|
Non-Disclosure of Proprietary Information
. Employee recognizes and acknowledges that the Trade Secrets (as defined below) and Confidential Information (as defined below) of the Company and its affiliates and all physical embodiments thereof (as they may exist from time-to-time, collectively, the “Proprietary Information”) are valuable, special and unique assets of the Company's and its affiliates' businesses. Employee further acknowledges that access to such Proprietary Information is essential to the performance of Employee's duties under this Agreement. Therefore, in order to obtain access to such Proprietary Information, Employee agrees that, except with respect to those duties assigned to him by the Company, Employee will hold in confidence all Proprietary Information and will not reproduce, use, distribute, disclose, publish or otherwise disseminate any Proprietary Information, in whole or in part, and will take no action causing, or fail to take any action necessary to prevent causing, any Proprietary Information to lose its character as Proprietary Information, nor will Employee make use of any such information for Employee's own purposes or for the benefit of any person, firm, corporation, association or other entity (except the Company) under any circumstances.
For purposes of this Agreement, the term “Trade Secrets” means information, including, but not limited to, any technical or nontechnical data, formula, pattern, compilation, program, device, method, technique, drawing, process, financial data, financial plan, product plan, list of actual or potential customers or suppliers, or other information similar to any of the foregoing, which derives economic value, actual or potential, from not being generally known to, and not being readily ascertainable by proper means by, other persons who can derive economic value from its disclosure or use. For purposes of this Agreement, the term “Trade Secrets” does not include information that Employee can show by competent proof (i) was known to Employee and reduced to writing prior to disclosure by the Company (but only if Employee promptly notifies the Company of Employee’s prior knowledge); (ii) was generally known to the public at the time the Company disclosed the information to Employee; (iii) became generally known to the public after disclosure by the Company through no act or omission of Employee; or (iv) was disclosed to Employee by a third party having a bona fide right both to possess the information and to disclose the information to Employee. The term “Confidential Information” means any data or information of the Company, other than trade secrets, which is valuable to the Company and not generally known to competitors of the Company. The provisions of this Section 6 will apply to Trade Secrets for so long as such information remains a trade secret and to Confidential Information during Employee’s employment with the Company and for a period of two (2) years following any termination of Employee’s employment with the Company for whatever reason.
|
|
11.
Non-Solicitation Covenants
. Employee agrees that during Employee's employment by the Company and for a period of two (2) year following the termination of Employee's employment for whatever reason, Employee will not, directly or indirectly, on Employee's own behalf or in the service of or on behalf of any other individual or entity, divert, solicit or attempt to divert or solicit any individual or entity (i) who is a client of the Company at any time during the six (6)-month period prior to Employee's termination of employment with the Company (“Client”), or was actively sought by the Company as a prospective client, and (ii) with whom Employee had material contact while employed by the Company to provide similar services or products as such provided by Employee for the Company to such Clients or prospects. Employee further agrees and represents that during Employee's employment by the Company and for a period of two (2) year following any termination of Employee's employment for whatever reason, Employee will not, directly or indirectly, on Employee's own behalf or in the service of, or on behalf of any other individual or entity, divert, solicit or hire away, or attempt to divert, solicit or hire away, to or for any individual or entity which is engaged in providing similar services or products to that provided by the Company, any person employed by the Company for whom Employee had supervisory responsibility or with whom Employee had material contact while employed by the Company, whether or not such employee is a full-time employee or temporary employee of the Company, whether or not such employee is employed pursuant to written agreement and whether or not such employee is employed for a determined period or at-will. For purposes of this Agreement, “material contact” exists between Employee and a Client or potential Client when (1) Employee established and/or nurtured the Client or potential Client; (2) the Client or potential Client and Employee interacted to further a business relationship or contract with the Company; (3) Employee had access to confidential information and/or marketing strategies or programs regarding the Client or potential Client; and/or (4) Employee learned of the Client or potential Client through the efforts of the Company providing Employee with confidential Client information, including but not limited to the Client’s identify, for purposes of furthering a business relationship.
|
|
12.
Existing Restrictive Covenants
. Except as provided in Exhibit B, Employee has not entered into any agreement with any employer or former employer: (a) to keep in confidence any confidential information, or (b) to not compete with any former employer. Employee represents and warrants that Employee's employment with the Company does not and will not breach any agreement which Employee has with any former employer to keep in confidence confidential information or not to compete with any such former employer. Employee will not disclose to the Company or use on its behalf any confidential information of any other party required to be kept confidential by Employee.
|
|
13.
Return of Proprietary Information
. Employee acknowledges that as a result of Employee's employment with the Company, Employee may come into the possession and control of Proprietary Information, such as proprietary documents, drawings, specifications, manuals, notes, computer programs, or other proprietary material. Employee acknowledges, warrants and agrees that Employee will return to the Company all such items and any copies or excerpts thereof, and any other properties, files or documents obtained as a result of Employee's employment with the Company, immediately upon the termination of Employee's employment with the Company.
|
|
14.
Proprietary Rights
. During the course of Employee's employment with the Company, Employee may make, develop or conceive of useful processes, machines, compositions of matter, computer software, algorithms, works of authorship expressing such algorithm, or any other discovery, idea, concept, document or improvement which relates to or is useful to the Company's Business (the “Inventions”), whether or not subject to copyright or patent protection, and which may or may not be considered Proprietary Information. Employee acknowledges that all such Inventions will be “works made for hire” under United States copyright law and will remain the sole and exclusive property of the Company. Employee also hereby assigns and agrees to assign to the Company, in perpetuity, all right, title and interest Employee may have in and to such Inventions, including without limitation, all copyrights, and the right to apply for any form of patent, utility model, industrial design or similar proprietary right recognized by any state, country or jurisdiction. Employee further agrees, at the Company's request and expense, to do all things and sign all documents or instruments necessary, in the opinion of the Company, to eliminate any ambiguity as to the ownership of, and rights of the Company to, such Inventions, including filing copyright and patent registrations and defending and enforcing in litigation or otherwise all such rights.
Employee will not be obligated to assign to the Company any Invention made by Employee while in the Company's employ which does not relate to any business or activity in which the Company is or may reasonably be expected to become engaged, except that Employee is so obligated if the same relates to or is based on Proprietary Information to which Employee will have had access during and by virtue of Employee's employment or which arises out of work assigned to Employee by the Company. Employee will not be obligated to assign any Invention which may be wholly conceived by Employee after Employee leaves the employ of the Company, except that Employee is so obligated if such Invention involves the utilization of Proprietary Information obtained while in the employ of the Company. Employee is not obligated to assign any Invention that relates to or would be useful in any business or activities in which the Company is engaged if such Invention was conceived and reduced to practice by Employee prior to Employee's employment with the Company. Employee agrees that any such Invention is set forth on Exhibit “A” to this Agreement.
|
|
15.
Remedies
. Employee agrees and acknowledges that the violation of any of the covenants or agreements contained in Sections 10 through 14 of this Agreement would cause irreparable injury to the Company, that the remedy at law for any such violation or threatened violation thereof would be inadequate, and that the Company will be entitled, in addition to any other remedy, to temporary and permanent injunctive or other equitable relief without the necessity of proving actual damages or posting a bond.
|
|
16.
Severability
. In case one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, the parties agree that it is their intent that the same will not affect any other provision in this Agreement, and this Agreement will be construed as if such invalid or illegal or unenforceable provision had never been contained herein. It is the intent of the parties that this Agreement be enforced to the maximum extent permitted by law.
|
|
17.
Entire Agreement
. This Agreement embodies the entire agreement of the parties relating to the subject matter of this Agreement and supersedes all prior agreements, oral or written, regarding the subject matter hereof. No amendment or modification of this Agreement will be valid or binding upon the parties unless made in writing and signed by the parties.
|
|
18.
Governing Law
. This Agreement is entered into and will be interpreted and enforced pursuant to the laws of the State of New Jersey. The parties hereto hereby agree that the appropriate forum and venue for any disputes between any of the parties hereto arising out of this Agreement shall be any federal court in the state where the Employee has his principal place of residence and each of the parties hereto hereby submits to the personal jurisdiction of any such court. The foregoing shall not limit the rights of any party to obtain execution of judgment in any other jurisdiction. The parties further agree, to the extent permitted by law, that a final and unappealable judgment against either of them in any action or proceeding contemplated above shall be conclusive and may be enforced in any other jurisdiction within or outside the United States by suit on the judgment, a certified exemplified copy of which shall be conclusive evidence of the fact and amount of such judgment.
|
|
19.
Surviving Terms
. Sections 4, 10, 11, 14, 15 and 18 of this Agreement shall survive termination of this Agreement.
|
COMPANY: | EMPLOYEE: | |||
CICERO, INC. | ||||
/s/
|
/s/
|
|||
Name
|
John P. Broderick
|
|||
Title
|
|
________________________________
Employee Initials
|
1.
|
Employment
. The Company hereby employs Employee and Employee hereby accepts such employment upon the terms and conditions set forth in this Agreement.
|
2.
|
Duties of Employee
. Employee will be based in Georgia or North Carolina at the discretion of the Company. Employee’s title will be Chief Technology Officer and Employee will report directly to the Chief Executive Officer. Employee agrees to perform and discharge such other duties as may be assigned to Employee from time to time by the Company to the reasonable satisfaction of the Board of Directors, and such duties will be consistent with those duties regularly and customarily assigned by the Company to the position of Chief Technology Officer. Employee agrees to comply with all of the Company's policies, standards and regulations and to follow the instructions and directives as promulgated by the Board of Directors of the Company (“Policies”). Employee will devote Employee's full professional and business-related time, skills and best efforts to such duties and will not, during the term of this Agreement, be engaged (whether or not during normal business hours) in any other business or professional activity, whether or not such activity is pursued for gain, profit or other pecuniary advantage, without the prior written consent of the Board of Directors of the Company. This Section will not be construed to prevent Employee from (a) investing personal assets in businesses which do not compete with the Company in such form or manner that will not require any services on the part of Employee in the operation or the affairs of the companies in which such investments are made and in which Employee's participation is solely that of an investor; (b) purchasing securities in any corporation whose securities are listed on a national securities exchange or regularly traded in the over-the-counter market, provided that Employee at no time owns, directly or indirectly, in excess of one percent (1%) of the outstanding stock of any class of any such corporation engaged in a business competitive with that of the Company; or (c) participating in conferences, preparing and publishing papers or books, teaching or joining or participating in any professional associations or trade group, so long as the Board of Directors of the Company approves such participation, preparation and publication or teaching prior to Employee’s engaging therein.
|
3.
|
Term
. The term of this Agreement will be at-will, and can be terminated by either party at any time, with or without cause, subject to the provisions of Section 4 of this Agreement. Subject to the provisions of Section 4, this Agreement will cover the period January 01, 2012 through December 31, 2012 and thereafter successive annual periods unless a party provides the other with written notice of its intention to terminate this Agreement, which notice shall be delivered no later than thirty (30) days prior to the expiration of the initial term or any renewal term, as applicable.
|
4.
|
Termination
.
|
|
(a)
|
Termination by Company for Cause
. The Company may terminate this Agreement and all of its obligations hereunder immediately, including the obligation to pay Employee severance, vacation pay or any further accrued benefits or remuneration, if any of the following events occur:
|
|
(i)
|
Employee improperly performs, or fails to perform, his duties and responsibilities or materially breaches any of the terms or conditions set forth in this Agreement, a Policy, or invention assignment, confidentiality, non-solicitation or non-competition agreement with or for the benefit of the Company, SOAdesk, LLC (“SOAdesk”) or Vertical Thought, Inc. (“VTI”) and fails to cure such breach within ten (10) days after Employee's receipt from the Company of written notice of such breach (notwithstanding the foregoing, no cure period shall be applicable to breaches by Employee of Sections 10 through 14 of this Agreement or of provisions of such Policies or agreements relating to any thereof);
|
(ii)
|
Employee commits any other act materially detrimental to the business or reputation of the Company;
|
(iii)
|
Employee engages in willful misconduct, including fraud or intentional misrepresentation;
|
(iii)
|
Employee engages in dishonest activities or commits or is convicted of, or pleads guilty or nolo contendere to, any felony or a misdemeanor involving fraud, deceit, moral turpitude or unethical business conduct;
|
(iv)
|
Employee engages in habitual alcohol or drug abuse that continues after written notice from the Company, which abuse has (a) had an adverse effect on Employee’s productivity or ability to carry out his duties under this Agreement, (b) jeopardized the safety of any other employee of the Company or any person having business relations with the Company, (c) damaged the reputation of the Company, or (d) endangered the Company’s ability to compete for business; or
|
|
(v)
|
Employee dies or becomes mentally or physically incapacitated or disabled so as to be unable to perform Employee's duties under this Agreement even with a reasonable accommodation. Without limiting the generality of the foregoing, Employee's inability adequately to perform services under this Agreement for a period of sixty (60) consecutive days will be conclusive evidence of such mental or physical incapacity or disability, unless such inability is pursuant to a mental or physical incapacity or disability covered by the Family Medical Leave Act, in which case such sixty (60) day period shall be extended to a one hundred and twenty (120) day period.
|
|
(b)
|
Termination by Company Without Cause
. The Company may terminate Employee's employment pursuant to this Agreement for reasons other than those stated in Section 4(a) upon at least thirty (30) days' prior written notice to Employee. In the event Employee's employment with the Company is terminated by the Company without cause, and subject to the execution by Employee and effectiveness of a customary release in a form reasonably satisfactory to the Company, the Company shall be obligated to pay Employee severance payments equal to six (6) months of Employee’s then base salary in the aggregate. In addition, Employee will be entitled to payment of all unused vacation days at his current daily rate and any accrued but unpaid salary or earned bonuses. The foregoing severance and other payments shall be payable (subject to the effectiveness of such customary release) in equal semi-monthly installments over the six (6) month period following Employee’s termination in accordance with the Company’s standard payroll practices. Employee will be entitled to receive no further remuneration and will not be entitled to participate in any Company benefit programs following his termination by the Company, whether such termination is with or without cause.
|
|
(a)
|
Annual Salary
. During the term of this Agreement and for all services rendered by Employee under this Agreement, the Company will pay Employee a base salary of One Hundred and Fifty Thousand Dollars ($150,000.00) per annum in equal semi-monthly installments.
|
|
(b)
|
Incentive Compensation
. Employee is eligible for an annual bonus upon the Company reaching certain pre tax income levels (after accounting for all bonuses) as set forth in Exhibit C. Said bonus will be payable after the annual accounts have been presented to the Compensation Committee. Exhibit C attached hereto provides the benchmarks associated with achieving the Incentive Compensation.
|
|
(c)
|
Equity Awards
. Employee is eligible for stock option grants and restricted stock awards as determined by the Compensation Committee.
|
6.
|
Vacation.
Employee shall be eligible for four (4) weeks of paid vacation annually, provided that such vacation is scheduled at such times that do not interfere with the Company’s legitimate business needs.
|
7.
|
Other Benefits
. Employee will be entitled to such fringe benefits as may be provided from time-to-time by the Company to its employees, including, but not limited to, group health insurance, life and disability insurance, and any other fringe benefits now or hereafter provided by the Company to its employees, if and when Employee meets the eligibility requirements for any such benefit. The Company reserves the right to change or discontinue any employee benefit plans or programs now being offered to its employees; provided, however, that all benefits provided for employees of the same position and status as Employee will be provided to Employee on an equal basis.
|
8.
|
Business Expenses
. Employee will be reimbursed for all reasonable expenses incurred in the discharge of Employee's duties under this Agreement pursuant to the Company's standard reimbursement policies.
|
9.
|
Withholding
. The Company will deduct and withhold from the payments made to Employee under this Agreement, state and federal income taxes, FICA and other amounts normally withheld from compensation due employees.
|
10.
|
Non-Disclosure of Proprietary Information
. Employee recognizes and acknowledges that the Trade Secrets (as defined below) and Confidential Information (as defined below) of the Company and its affiliates, including for purposes of this Section 10 any of the same purchased from SOAdesk or VTI, and all physical embodiments thereof (as they may exist from time-to-time, collectively, the “Proprietary Information”) are valuable, special and unique assets of the Company's and its affiliates' businesses. Employee further acknowledges that access to such Proprietary Information is essential to the performance of Employee's duties under this Agreement. Therefore, in order to obtain access to such Proprietary Information, Employee agrees that, except with respect to those duties assigned to him by the Company, Employee will hold in confidence all Proprietary Information and will not reproduce, use, distribute, disclose, publish or otherwise disseminate any Proprietary Information, in whole or in part, and will take no action causing, or fail to take any action necessary to prevent causing, any Proprietary Information to lose its character as Proprietary Information, nor will Employee make use of any such information for Employee's own purposes or for the benefit of any person, firm, corporation, association or other entity (except the Company) under any circumstances.
|
11.
|
Non-Solicitation Covenants
. Employee agrees that during Employee's employment by the Company and for a period of two (2) year following the termination of Employee's employment for whatever reason, Employee will not, directly or indirectly, on Employee's own behalf or in the service of or on behalf of any other individual or entity, divert, solicit or attempt to divert or solicit any individual or entity (i) who is a client of the Company or SOAdesk at any time during the six (6)-month period prior to Employee's termination of employment with the Company (“Client”), or was actively sought by the Company or SOAdesk as a prospective client, and (ii) with whom Employee had material contact while employed by or providing services to or for the benefit of the Company, SOAdesk or VTI to provide similar services or products as such provided by Employee for the Company, SOAdesk or VTI to such Clients or prospects. Employee further agrees and represents that during Employee's employment by the Company and for a period of two (2) year following any termination of Employee's employment for whatever reason, Employee will not, directly or indirectly, on Employee's own behalf or in the service of, or on behalf of any other individual or entity, divert, solicit or hire away, or attempt to divert, solicit or hire away, to or for any individual or entity which is engaged in providing similar services or products to that provided by the Company, SOAdesk or VTI, any person employed by the Company for whom Employee had supervisory responsibility or with whom Employee had material contact while employed by or providing services to or for the benefit of the Company, SOAdesk or VTI, whether or not such employee is a full-time employee or temporary employee of the Company, whether or not such employee is employed pursuant to written agreement and whether or not such employee is employed for a determined period or at-will. For purposes of this Agreement, “material contact” exists between Employee and a Client or potential Client when (1) Employee established and/or nurtured the Client or potential Client; (2) the Client or potential Client and Employee interacted to further a business relationship or contract with the Company, SOAdesk or VTI; (3) Employee had access to confidential information and/or marketing strategies or programs regarding the Client or potential Client; and/or (4) Employee learned of the Client or potential Client through the efforts of the Company, SOAdesk or VTI providing Employee with confidential Client information, including but not limited to the Client’s identify, for purposes of furthering a business relationship.
|
12.
|
Existing Restrictive Covenants
. Except as provided in Exhibit B, Employee has not entered into any agreement with any employer or former employer: (a) to keep in confidence any confidential information, or (b) to not compete with any former employer. Employee represents and warrants that Employee's employment with the Company does not and will not breach any agreement which Employee has with any former employer to keep in confidence confidential information or not to compete with any such former employer. Employee will not disclose to the Company or use on its behalf any confidential information of any other party required to be kept confidential by Employee.
|
13.
|
Return of Proprietary Information
. Employee acknowledges that as a result of Employee's employment with the Company, Employee may come into the possession and control of Proprietary Information, such as proprietary documents, drawings, specifications, manuals, notes, computer programs, or other proprietary material. Employee acknowledges, warrants and agrees that Employee will return to the Company all such items and any copies or excerpts thereof, and any other properties, files or documents obtained as a result of Employee's employment with the Company, immediately upon the termination of Employee's employment with the Company.
|
14.
|
Proprietary Rights
. During the course of Employee's employment with the Company, Employee may make, develop or conceive of useful processes, machines, compositions of matter, computer software, algorithms, works of authorship expressing such algorithm, or any other discovery, idea, concept, document or improvement which relates to or is useful to the Company's Business (the “Inventions”), whether or not subject to copyright or patent protection, and which may or may not be considered Proprietary Information. Employee acknowledges that all such Inventions will be “works made for hire” under United States copyright law and will remain the sole and exclusive property of the Company. Employee also hereby assigns and agrees to assign to the Company, in perpetuity, all right, title and interest Employee may have in and to such Inventions, including without limitation, all copyrights, and the right to apply for any form of patent, utility model, industrial design or similar proprietary right recognized by any state, country or jurisdiction. Employee further agrees, at the Company's request and expense, to do all things and sign all documents or instruments necessary, in the opinion of the Company, to eliminate any ambiguity as to the ownership of, and rights of the Company to, such Inventions, including filing copyright and patent registrations and defending and enforcing in litigation or otherwise all such rights.
|
15.
|
Remedies
. Employee agrees and acknowledges that the violation of any of the covenants or agreements contained in Sections 10 through 14 of this Agreement would cause irreparable injury to the Company, that the remedy at law for any such violation or threatened violation thereof would be inadequate, and that the Company will be entitled, in addition to any other remedy, to temporary and permanent injunctive or other equitable relief without the necessity of proving actual damages or posting a bond.
|
16.
|
Severability
. In case one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, the parties agree that it is their intent that the same will not affect any other provision in this Agreement, and this Agreement will be construed as if such invalid or illegal or unenforceable provision had never been contained herein. It is the intent of the parties that this Agreement be enforced to the maximum extent permitted by law.
|
17.
|
Entire Agreement
. This Agreement embodies the entire agreement of the parties relating to the subject matter of this Agreement and supersedes all prior agreements, oral or written, regarding the subject matter hereof. No amendment or modification of this Agreement will be valid or binding upon the parties unless made in writing and signed by the parties.
|
18.
|
Governing Law
. This Agreement is entered into and will be interpreted and enforced pursuant to the laws of the State of North Carolina. The parties hereto hereby agree that the appropriate forum and venue for any disputes between any of the parties hereto arising out of this Agreement shall be any federal court in the state where the Employee has his principal place of residence and each of the parties hereto hereby submits to the personal jurisdiction of any such court. The foregoing shall not limit the rights of any party to obtain execution of judgment in any other jurisdiction. The parties further agree, to the extent permitted by law, that a final and unappealable judgment against either of them in any action or proceeding contemplated above shall be conclusive and may be enforced in any other jurisdiction within or outside the United States by suit on the judgment, a certified exemplified copy of which shall be conclusive evidence of the fact and amount of such judgment.
|
19.
|
Surviving Terms
. Sections 4, 10, 11, 13, 14, 15 and 18 of this Agreement shall survive termination of this Agreement.
|
COMPANY: | EMPLOYEE: | |||
CICERO, INC.
|
|
By: | |||||
Name
|
Antony Castagno | ||||
Title
|
A.
|
Vendor develops, manufactures and distributes certain software products through reseller channels.
|
B.
|
Convergys is engaged in the business of developing and distributing computer software products to end users and providing them with installation, integration, support and training services, providing software solutions to end users to support business processes and business process outsourcing activities.
|
C.
|
The parties desire to set forth the terms and conditions under which Convergys will acquire from Vendor a license to (i) use the Product and the Source Code to create Derivative Products and Composite Products and (ii) to distribute to End Customers and use internally the Product, Derivative Products and Composite Products in the Territory (as each such term is defined below).
|
|
1.
|
Definitions
.
|
(a)
|
“Convergys Software” shall mean the computer software products and associated documentation, developed by Convergys or for Convergys as work for hire, in which Convergys retains the right, title and interest to the deliverables of such work for hire.
|
(b)
|
"Composite Product" shall mean any application or solution developed by Convergys and delivered to End Customers of which the Product, a part of the Product or a Derivative Product is a part. Any Composite Product must include Convergys’ Dynamic Decisioning Solution or successor product..
|
(c)
|
"Confidential Information" shall mean: (i) information furnished by either party to this Agreement which is considered and specifically identified in writing as confidential, private or proprietary by the party furnishing the information at the time of disclosure (or if such Confidential Information is disclosed orally, it is identified as confidential or proprietary at the time of disclosure);(ii) the existence of this Agreement and the terms thereof; and (iii) information furnished by either party to this Agreement which is treated as confidential by the disclosing party and would reasonably be understood by the recipient to be confidential, whether or not so marked. .Neither party shall be required to protect or hold in confidence any information received by it which:
|
(i)
|
is or becomes available to the public or to the industry without the fault of the recipient;
|
(ii)
|
was rightfully in the possession of recipient before being provided to the recipient by the other party;
|
(iii)
|
is independently developed by the recipient;
|
(iv)
|
is required to be disclosed by court order, or other legal requirement, provided, however, that the recipient provides sufficient notice to the other party, if possible, to permit such other party an opportunity to obtain sufficient protective measures with regard to the information;
|
(v)
|
is subsequently received by the recipient without obligation of confidentiality from a third party, who the recipient had no reason to believe was not legitimately authorized to provide it with such information; or
|
(vi)
|
is not marked with a legend indicating that the same is proprietary, private or confidential.
|
(d)
|
“Derivative Product” means an executable runtime copy of a derivative work created by Convergys from the Source Code.
|
(e)
|
“Documentation” means the standard technical specification documentation accompanying the Product.
|
(f)
|
"End Customer" shall mean a person or entity that is granted a sublicense to use one or more Composite Products for that person’s or entity's own personal or internal business use, and who does not resell, lease, license, sublicense or otherwise distribute or transfer such Composite Product to others.
|
(g)
|
“Error” shall mean a failure of the Product to conform in all material respects with the applicable Documentation.
|
(h)
|
“MSP Services” shall mean selected services of Convergys, which include provision of access to, and management by Convergys of, the Composite Products on behalf of End Customers, where the Composite Products may be installed on computer systems or networks owned, managed or otherwise controlled by an End Customer, Convergys, or a third party colocation hosting facility.
|
(i)
|
“Product” shall mean Cicero’s XM™ Enterprise product
.
|
(j)
|
"Proprietary Rights of Vendor" shall mean all rights held by Vendor in the Product and its Confidential Information and/or Vendor Data, including, without limitation, patents, inventions, copyrights, author's rights, trademarks, service marks, trade names, know-how and trade secrets embodied in or associated with the foregoing, irrespective of whether such rights arise under U.S. or international intellectual property, unfair competition or trade secret laws.
|
(k)
|
"Proprietary Rights of Convergys" shall mean all rights held by Convergys in the Convergys Software and its other Confidential Information, including, without limitation, patents, inventions, copyrights, authors' rights, trademarks, trade names, service marks, know-how and trade secrets embodied in or associated with the foregoing, irrespective of whether such rights arise under U.S. or international intellectual property, unfair competition or trade secret laws.
|
(l)
|
“Release” shall mean a new version of the Product designated by a change to the number to the left of the decimal point (R.xx).
|
(m)
|
“Reseller(s)” shall mean Convergys’s third party resellers or distributors to whom Convergys grants the right to resell Composite Products under terms substantially similar to those contained in this Agreement regarding licensing and protection of the Proprietary Rights of Vendor.
|
(n)
|
“Seat” shall mean a single agent workstation.
|
(o)
|
“Source Code” shall mean the source code and any associated computer software libraries, documentation and other materials for the Product set forth in Exhibit A as provided to Convergys in accordance with Section 11.
|
(p)
|
“Specifications” shall mean the standard Documentation for the Product specified on Exhibit A as delivered by Vendor.
|
(q)
|
“System Identifier” shall mean a string of characters designated by Convergys which uniquely identifies the system or systems associated with a given Product license, distributed to an End Customer as a Composite Product, or used internally by Convergys which Convergys shall report quarterly to Vendor as Product licenses are distributed or deployed internally, and which Convergys shall track in such a manner as to allow Convergys or Vendor to determine at any given time how many Product licenses have been distributed, what license fees have been paid, and what are due and owed to Vendor.
|
(r)
|
"Territory" shall mean the parts of the world where Convergys can purchase and resell the Composite Products. For purposes of this Agreement, the Territory shall be worldwide, subject to the export restrictions herein.
|
(s)
|
“Vendor Data” shall mean all Vendor Confidential Information provided by Vendor under this Agreement or any Work Order hereto.
|
(t)
|
"Version” shall mean a new version of the Product designated by a change to the digit to the right of the decimal point (x.V).
|
|
2.
|
License Grant
.
|
|
Subject to the terms of this Agreement, Vendor grants to Convergys the following perpetual, world-wide, non-exclusive, non-transferable licenses (each, a “License”):
|
|
Any and all rights granted under this Section 2 are perpetual and shall survive termination of the Agreement. For the avoidance of doubt, a license will be for a Seat.
|
|
3.
|
Payment; Taxes; Audits
.
|
|
(a)
|
Payments Due
. Convergys shall pay Vendor the fees set forth in Exhibit B.
|
|
(e)
|
Taxes
. All amounts payable under this Agreement are exclusive of all sales, use, value-added, withholding and similar taxes and duties. Convergys shall pay all taxes and duties assessed in connection with Convergys's performance under this Agreement by any authority within or outside of the U.S., except for taxes payable on Vendor's net income.
|
|
4.
|
Training
. Vendor will provide training for Convergys's personnel at such time and for such consideration as is set forth on the attached Exhibit D.
|
|
5.
|
Literature.
Convergys shall have a royalty free right to modify, use, copy and distribute the Documentation in order to support the sales, licensing, use, and support of the Product or a Derivative Product.
|
|
6.
|
Confidentiality and Intellectual Property Rights
.
|
|
(a)
Confidentiality
. Each party agrees, in the event it receives Confidential Information of the other, to use such Confidential Information only for the purposes for which it was disclosed to the party, to exercise reasonable care to protect and hold such Confidential Information in confidence and to prevent its disclosure to third parties, except as permitted under this Agreement. Neither Vendor nor Convergys shall disclose, and each of Vendor and Convergys shall maintain the confidentiality of, all Confidential Information of the other party. Each of Vendor and Convergys shall use at least the same degree of care to safeguard and to prevent disclosing to third parties the Confidential Information of the other as it employs to avoid unauthorized disclosure, publication, dissemination, destruction, loss, or alteration of its own like information (or information of its customers) of a similar nature, but not less than reasonable care, for a period of three (3) years after termination of this Agreement. Each party will only disclose Confidential Information to its employees having a need to know for the purposes of this Agreement. Each party will notify and inform such employees of each party's limitations, duties, and obligations regarding use, access to, and nondisclosure of Confidential Information and will obtain or have obtained its employees' agreements to comply with such limitations, duties, and obligations. Each party agrees to give notice to the other party promptly, but in no event no more than one (1) business day, after learning of a breach of any of the proprietary restrictions set forth in this Section. In the event that a party is required to disclose Confidential Information pursuant to law, that party will notify the other party of the required disclosure with sufficient time to seek relief, cooperate with the other party in taking appropriate protective measures, and will make such disclosure in the fashion which maximizes protection of the Confidential Information from further disclosure. Upon termination of this Agreement, all such Confidential Information will be returned to the disclosing party.
|
|
(b)
|
Intellectual Property Rights
. Vendor and Convergys acknowledge and agree that Vendor owns all of the Proprietary Rights of Vendor, which includes the Product and Documentation, and that Convergys has no right, title or interest therein other than as granted pursuant to this Agreement. Vendor represents and warrants to Convergys that all intellectual property rights in the Product and Documentation are owned by Vendor, and that the Proprietary Rights of Vendor are sufficient to grant the rights granted to Convergys under this Agreement. Vendor and Convergys acknowledge and agree that Convergys owns all the Proprietary Rights of Convergys and that Vendor has no rights, title or interest therein other than as granted pursuant to this Agreement.
|
|
(c)
|
Unless otherwise specified in a Work Order, Vendor agrees that anything (excepting only Proprietary Rights of Vendor) created or developed in whole or in part by Convergys, including, without limitation, any and all programming, Internet related software or processes, software source code which is a derivative work of Vendor’s Source Code, interactive voice response related software or processes, software modifications and customizations, application program interfaces, telephone marketing related software, telephone marketing or business methods, statistical research and analysis, call disposition data, training methods or training materials or other telephone marketing related information, methods or processes (collectively, "Convergys Works"), are and shall remain the sole and exclusive property of Convergys, free and clear of any and all claims of Vendor. Convergys’ reservation of proprietary rights shall apply (i) to the extent that the above-mentioned Convergys Works are made by Convergys, and (ii) if such are made by Convergys, to the extent they are not severable from the original information, data and other matter which are trade secrets and/or proprietary to Vendor. “Convergys Works” shall not be deemed to include the Vendor Data or any Proprietary Rights of Vendor.
|
|
(d)
No Other Rights
. Convergys may not, directly or through any person or entity, in any form or manner, copy, distribute, reproduce, incorporate, use or allow access to the Product or modify, prepare derivative works of, decompile, reverse engineer, disassemble or otherwise attempt to derive source code or object code from the Product, except as explicitly permitted under this Agreement or otherwise agreed in writing. Convergys will take appropriate steps with the End Customers to inform them of and assure their compliance with the restrictions contained in this Agreement.
|
|
(e)
|
Private Labeling
. Convergys may, in its absolute and sole discretion, private label or brand the Product acquired under this Agreement or any Derivative Product. If Convergys determines to private label or brand the Product or a Derivative Product, Convergys may do so using any name, mark, trade name, brand and\or trademark that it chooses. Any such names, marks, trade names, brands and\or trademarks may be displayed on or with the Product or Derivative Products in any manner chosen by Convergys. Convergys will have no obligation to in any way display or use any name, mark, trade name, brand or trademark of Vendor on or with any products that Convergys chooses to private label or brand. Nothing herein will in any way convey to either party any right, title or interest in any names, marks, trade names, brands and\or trademarks of the other party. Convergys may also, if it so chooses, display any name, mark, trade name brand or trademark of Vendor in accordance with any reasonable instructions conveyed to Convergys in writing in accordance with the notice provisions of this Agreement. Vendor hereby grants to Convergys a limited, non-exclusive, non-transferable license to use Vendor’s name, mark, trade name, brand or trademark, for the sole purpose of marketing and distributing the Product for sale as permitted by this Agreement. All goodwill in any mark or brand name of Convergys shall belong exclusively to Convergys.
|
|
7.
|
Indemnity
.
|
|
(a)
|
Indemnification Against Infringement by Vendor
. Vendor will indemnify, hold harmless and defend Convergys at its own expense (including reasonable attorneys’ fees) against any claim that any Product or any of the Deliverables provided by Vendor hereunder, infringes any copyright, patent, trade mark or trade secret, provided that Convergys promptly notifies Vendor of any such claim after receiving service of process, provides all reasonable assistance to Vendor and allows Vendor to control any resulting litigation and\or settlement negotiations. Vendor shall have no obligation with respect to any such claim of infringement to the extent it is based upon Convergys's modification of any Product or any of the Deliverables or their combination, operation, or use with apparatus, data or computer programs not furnished by Vendor and not reasonably contemplated under this Agreement. If a claim of infringement described in this paragraph does occur, or in Vendor's opinion is likely to occur, Convergys will permit Vendor, at its option and expense, (i) to modify the Product or a Deliverable so that it is no longer infringing while performing substantially the same function, (ii) to obtain for Convergys the right to continue using the Product or Deliverable, or (iii) terminate the right to use the Product or Deliverable, upon which termination Vendor will refund Convergys’s license fees paid for the Product or Deliverable.
|
|
(b)
|
General Indemnification by Vendor
. Vendor agrees to indemnify and hold Convergys harmless from and against any cost, loss, expense (including attorney’s fees) resulting from any and all claims by third parties for loss, damage or injury (including death) allegedly caused by the Product or Deliverables, or any portions thereof, purchased or licensed by Convergys, and whether or not distributed by Convergys, including, without limitation, any claim resulting from the acts, representations, or omissions of Vendor with respect to the Product or any part or parts thereof. Convergys shall have the right to participate at its expense in any such dispute. Notwithstanding the foregoing, Vendor assumes no liability hereunder for claims or actions to the extent they result from or arise from modifications made to the Product or Deliverables by anyone other than Vendor or from Convergys's sole negligence or intentional misconduct.
|
|
8.
|
Warranty; Insurance
.
|
|
(a)
|
Warranty.
The initial Release and Version of the Product delivered under this Agreement is warranted for a period of one hundred eighty (180) days from the Effective Date. Any subsequent Releases or Versions of the Product delivered to Convergys under the Agreement are warranted until the later of (x) ninety (90) days from delivery to Convergys or, (y) until completion of the knowledge transfer as set forth in Exhibit C. Vendor's warranty is contingent upon proper use and application of the Product in accordance with the Specifications and does not cover repair or replacement caused by: (i) failure to provide a suitable environment prescribed by Vendor; (ii) neglect, (iii) alterations or modifications which are not approved by Vendor; or (iv) maintenance or repair not performed by Vendor. Vendor shall, at its own option, correct any nonconformity of the Product with the Specifications which is reported to Vendor during the warranty period. If Vendor is unable to correct such nonconformity, or replace such copy of the Product within a reasonable period of time after such nonconformity is reported, Convergys’s sole remedy is that Vendor shall provide Convergys with a refund of the license fees for such copy and any fees for professional services, development, training and implementation in connection paid in connection with such copy, if Convergys has paid such fees. EXCEPT AS SET FORTH HEREIN, VENDOR DISCLAIMS ANY OTHER EXPRESS OR IMPLIED WARRANTY INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
|
|
(b)
|
Insurance.
Vendor will, during the Term, have and maintain in force the following insurance coverage:
|
(i).
|
Worker’s Compensation Insurance, including occupational illness or disease coverage, or other similar social insurance, including self-insurance, in accordance with the laws of the country, state or territory exercising jurisdiction over the employee and Employer’s Liability Insurance with a minimum limit sufficient to cover the statutory requirements of such country, state or territory.
|
(ii).
|
Commercial General Liability Insurance, including Contractual Liability, Products, Completed Operations Liability and Personal Injury, and Broad Form Property Damage Liability coverage for damages to any property with a minimum combined single limit of $1,000,000 per occurrence and $5,000,000 umbrella excess liability. Such insurance must name Convergys as an additional insured with respect to its legal liability arising from Vendor’s acts or omissions.
|
(iii).
|
Employee Dishonesty and Computer Fraud coverage for loss arising out of or in connection with any fraudulent or dishonest acts committed by the employees of Vendor, acting alone or in collusion with others, including the property and funds of others in their care, custody or control, in a minimum amount of $1,000,000.
|
(iv).
|
Errors and Omissions Liability Insurance covering the legal liability for damages due to error, omissions, negligence of employees and failure of Vendor’s products to perform the function or serve the purpose intended in an amount of at least $1,000,000 per wrongful act. Vendor will have and maintain in force Errors and Omissions Liability Insurance for a period of twelve (12) months after termination of this Agreement.
|
(v).
|
“All Risk” Property insurance covering not less than the full replacement cost of Vendor’s personal property while on or at a Convergys work location.
|
|
9.
|
Term and Termination
.
|
|
(a)
|
Term
. This Agreement shall become effective on the date first written on this Agreement and shall continue for an initial period ending December 31
st
, 2016 (the “Term”).
|
|
(b)
|
Termination for Cause
. This Agreement may be terminated for cause as set for the below:
|
|
(i)
|
Termination for Bankruptcy. This Agreement shall automatically be terminated upon the occurrence of any of the following events: either party shall apply for or consent to the appointment of or taking of possession by a receiver, custodian, trustee, or liquidator of itself or of all or a substantial part of its property, or make a general assignment for the benefit of creditors, or commence a voluntary case under the Federal Bankruptcy Code (as now or hereafter in effect) or any similar laws respecting debtors' and creditors' rights in any other jurisdiction, or fail to contest in a timely or appropriate manner or acquiesce in writing to any petition filed against it in an involuntary case under such Bankruptcy Code or any similar laws or any application for the appointment of a receiver, custodian, trustee, or liquidation of itself or of all or a substantial part of its property, or its reorganization, or dissolution or admit its inability to pay its debts as they become due. For proposes of this Section 9(c), the references to the parties hereto shall be deemed to include any firm or corporation controlling either party.
|
|
(ii)
|
Termination for Breach. In the event that either party materially defaults in the performance of any of its duties and obligations hereunder (other than a default described in Section 9(b)(i) above), which default shall not be substantially cured within thirty (30) days after written notice is given to the defaulting party specifying the default, then the party not in default may, upon giving written notice thereof to the defaulting party, terminate this Agreement upon written notice to the other party as of such thirtieth (30
th
) day.
|
|
10.
|
Limitation of Liability
.
|
|
(A) EXCEPT FOR (i) VENDOR’S OBLIGATIONS PURSUANT TO SECTION 7(a),AND (ii) EITHER PARTY’S OBLIGATIONS PURSUANT TO SECTION 6(a), OF THIS AGREEMENT, THE LIABILITY OF EACH PARTY HEREUNDER TO THE OTHER PARTY FOR ANY PARTICULAR CLAIM RELATING TO THE PRODUCTS AND SERVICES, WHETHER IN CONTRACT, TORT, OR OTHERWISE, SHALL NOT EXCEED THE GREATER OF THE ACTUAL PROVEN DIRECT DAMAGES, OR THE AMOUNT OF THE FEES PAYABLE TO VENDOR BY CONVERGYS UNDER THIS AGREEMENT, FOR THE PRODUCT OR SERVICE GIVING RISE TO THE CLAIM. EACH PARTY'S AGGREGATE LIABILITY FOR DAMAGES FOR ALL CLAIMS WHATSOEVER RELATING TO THE PRODUCTS AND SERVICES UNDER THIS AGREEMENT, AND WHETHER IN CONTRACT, TORT, OR OTHERWISE, SHALL BE LIMITED TO THE TOTAL AMOUNT OF THE FEES PAYABLE BY CONVERGYS TO VENDOR FOR THE PRODUCTS AND SERVICES UNDER THIS AGREEMENT.
|
|
(B) EXCEPT FOR (i) VENDOR'S OBLIGATIONS PURSUANT TO SECTION 7(a) AND (ii) EITHER PARTY’S OBLIGATIONS PURSUANT TO SECTION 6(a), OF THIS AGREEMENT, IN NO EVENT SHALL EITHER PARTY HAVE ANY LIABILITY TO THE OTHER PARTY, FOR ANY INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, LOSS OF BUSINESS OPPORTUNITY OR LOSS OF PROFITS.)HOWEVER CAUSED AND WHETHER ARISING UNDER CONTRACT, TORT OR OTHER THEORY OF LIABILITY, EVEN IF THE PARTY MAY HAVE BEEN INFORMED OF THEIR POSSIBILITY.
|
|
(C)
|
THESE LIMITATIONS SHALL APPLY NOTWITHSTANDING THE FAILURE OF THE ESSENTIAL PURPOSE OF ANY LIMITED REMEDY.
|
|
11.
|
Delivery and Knowledge Transfer
|
(a)
|
Deliverables
. Vendor shall, within five (5) days following the execution of this Agreement, provide Convergys with a copy of the materials set forth in Exhibit A for the most current Version of the Product, along with any computer libraries, documentation or other materials necessary to execute the rights granted to Convergys under the Agreement (“Deliverables’). In addition, Vendor shall deliver to Convergys copies of the same Deliverables for any new Releases or Versions of the Product which Vendor makes generally commercially available until such time as the Knowledge Transfer Project set forth in Exhibit C is complete.
|
(b)
|
Knowledge Transfer Training
. In order to enable to Convergys to become self-sufficient with regard to the Source Code, Vendor will provide training for Convergys personnel in the form of the Deliverables and Knowledge Transfer Project plan set forth in Exhibit C. Such training shall be free of charge. If the parties mutually agree that Vendor will travel to a Convergys location for this training, Convergys will be responsible to reimburse Vendor for pre-approved travel and expenses. Vendor will comply with Convergys’ current travel and expense policies.
|
(c)
|
Protection of Source Code
. Convergys agrees to treat the Source Code as Confidential Information under the Agreement. In addition, Convergys agrees to the following:
|
i.
|
Convergys will cause each of its employees who have access to the Source Code to agree in writing not to engage in the development of any software which is in direct competition with the Product at any time during the one (1) year following the last such access, and execute, prior to any such access, a confidentiality agreement with each employee protecting Vendor's intellectual property rights, with terms no less stringent than the terms and conditions of this Agreement.
|
ii.
|
Convergys shall limit access to the Source Code to those employees with a need to use the Source Code for the purposes set forth in this Agreement. No unauthorized employees, consultants, or vendors will have access to the Source Code unless and until they have been apprised of and acknowledge the confidential and proprietary nature of the Source Code and they have been trained with respect to the procedures designed to preserve its confidentiality.
|
iii.
|
Convergys will designate an officer-level employee (the "Responsible Manager") who will have responsibility for preserving the security of the Source Code at all times. The Responsible Manager will maintain a record of all persons who have access to the Source Code. Convergys will record and investigate all unauthorized attempts to gain access to the Source Code and will promptly notify Vendor of any loss, theft, or unauthorized use or disclosure of the Source Code. Convergys will make such records available to Vendor, at Vendor's reasonable request. Convergys will conduct periodic reviews to ensure compliance with the foregoing security requirements. Vendor will have the right to conduct a review of the reports pursuant to Convergys security reviews to confirm compliance with the foregoing security restrictions, including an interview of the Responsible Manager and an inspection of the records maintained by Convergys, on fifteen (15) days written notice. Upon Vendor's reasonable request (but in no event more frequently than once per calendar year), an officer-level employee of Convergys shall confirm in writing to Vendor that Convergys is in material compliance with the terms and conditions of this Agreement.
|
(d)
|
Until such time as the Deliverables and Knowledge Transfer Project set forth in Exhibit C are complete, Vendor shall notify Convergys at least three (3) business days in advance of ceasing normal business operations and provide Convergys with contact information for key employees with knowledge and responsibility for the development of the Product and facilitate discussions with such key employees regarding working for Convergys to continue development and maintenance of the Source Code of the Product.
|
|
12.
|
Miscellaneous
.
|
|
(a)
|
Assignment
. This Agreement will be binding upon and inure to the benefit of the parties hereto and their permitted successors and assigns. Notwithstanding the foregoing, neither this Agreement, nor any rights or obligations hereunder, may be assigned or otherwise transferred, whether by operation of law or otherwise by either party, without prior written consent of the other party, which consent shall not be unreasonably withheld, and any assignment or other transfer without such prior written consent will be null and void.
|
|
(b)
|
Independent Contractors
. The relationship of Vendor and Convergys established by this Agreement is that of independent contractors, and nothing contained in this Agreement will be construed (i) to give either party the power to direct and control the day-to-day activities of the other, (ii) to constitute the parties as partners, joint ventures, co-owners or otherwise as participants in a joint or common undertaking, or (iii) to allow either party to create or assume any obligation on behalf of the other for any purpose whatsoever.
|
|
(c)
|
Severability
. If one or more provisions of this Agreement are held to be unenforceable under applicable law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach mutually agreeable and enforceable replacement for such provision, then (x) such provision shall be excluded from this Agreement, (y) the balance of the Agreement shall be interpreted as if such provision were so excluded, and (z) the balance of the Agreement shall be enforceable in accordance with its terms.
|
|
(d)
|
Legal Expenses
. The prevailing party in any legal action brought by one party against the other and arising out of this Agreement shall be entitled, in addition to any other rights and remedies it may have, to reimbursement for its expenses, including court costs and reasonable attorney's fees.
|
|
(e)
|
Titles and Subtitles
. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.
|
|
(f)
|
Counterparts
. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.
|
|
(g)
|
Entire Agreement; Enforcement of Rights
. This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter herein and merges all prior discussions between them. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the party to be charged. The failure by either party to enforce any rights hereunder shall not be construed as a waiver of any rights of such party.
|
|
(h)
|
Governing Law
. The validity, construction and enforceability of this Agreement shall be governed in all respects by the law of Texas applicable to agreements negotiated, executed and performed in Texas, whether one or more of the parties shall be or hereafter become a resident of another state or country and without reference to conflict of laws principles.
|
|
(i)
|
Force Majeure
. If the performance of this Agreement or any obligations hereunder (except payment obligations) is prevented, restricted or interfered with by reason of fire or other casualty or accident, strikes or labor disputes, war or other violence, any law, order, proclamation, regulation, ordinance, demand or requirement of any government agency, or any other act or condition beyond the reasonable control of the parties hereto, the party so affected upon giving prompt notice to the other parties shall be excused from such performance during such prevention, restriction or interference.
|
|
(j)
|
Notices and Other Communication
. Notice by any party under this Agreement shall be in writing and personally delivered or given by registered mail, overnight courier, telecopy confirmed by mail, telefax or prepaid cable, addressed to the other party at its respective address or addresses given herein (or at any such other address as may be communicated in writing to the notifying party in writing) and shall be deemed to have been served when delivered or, if delivery is not accomplished by reason of some fault of the addressee, when tendered. Notices required under this Agreement shall be delivered to the addresses set forth below unless either party notifies the other party in writing of any changes in such addresses:
|
|
(k)
|
Compliance with Export Regulations and Other Laws
. Both parties by their signature hereto certify they will not transfer, directly or indirectly, any Product or software included in such Product, or technical information received from the other or any copies thereof, or any Derivative Product or Composite Product produced from such technical information, to any of the countries contained within the country groups for which special export or re-export approval is required under United States Government Regulation 15 C.F.R. Section 379.4 (f) (1). Each party shall comply and shall be required to comply with the rules and regulations under the U.S. Export Administration Act, the U.S. Anti-Boycott provisions, as well as all export regulations of the territory or other applicable jurisdiction to which the Product or a Derivative Product is exposed, as the same may be amended from time to time.
|
|
(l)
|
Vendor Conduct Guidelines
. Vendor hereby agrees to abide by the terms of the Convergys’ Vendor Conduct Guidelines (the “Guidelines”), which are posted and updated from time to time at the following website: http://convergys.com/company/corporate-responsibility/our-business-partners.php (the “Website”). Vendor shall ensure that it (and any Vendor employees, agents, consultants and subcontractors who provide goods or services to Vendor in support of Convergys) have read, understand, and agree to comply with the most recent version of the Guidelines. Vendor agrees that it will certify its compliance to the Guidelines at the Website, no less than once annually, by December 31st of each calendar year. For the avoidance of doubt, to the extent that this Agreement contains obligations regarding Vendor conduct which are similar to, but stricter than, those stated in the Guidelines, Vendor shall adhere to the more strict obligations. In addition, to the extent that any terms of this Agreement regarding Vendor conduct conflict with the terms of the Guidelines, Convergys and Vendor agree to interpret any such conflicts cumulatively and to resolve any potential conflicts in a manner that provides the highest standard of conduct and protection to Convergys.
|
|
(m)
|
Survival.
The following provisions shall survive expiration or termination of this Agreement: 1, 6, 7, 8, 9, 10, 11, and 12.
|
CONVERGYS CUSTOMER MANAGEMENT GROUP INC.
|
VENDOR
|
By:____________________________________
|
By:____________________________________
|
Name:__________________________________
|
Name:__________________________________
|
Title:___________________________________
|
Title:___________________________________
|
Date:___________________________________
|
Date:___________________________________
|
1.
|
General Items Required
|
a.
|
Roadmap of deposited items (for current release)
|
i.
|
A high level overview describing where key items are located on the deposit media, including a table of contents type of structure that allows quick access to material.
|
b.
|
A list of all skill sets necessary to support the code.
|
c.
|
Encryption methods and/or passwords necessary for access to deposited material.
|
i.
|
Any and all encryption methods and passwords necessary to access any and all materials delivered including any compressed or non-compressed files used with the materials deposited, including any and all software or hardware keys necessary for access to the deposit media.
|
d.
|
Tools or Software needed to create a clear-text version of the source code.
|
i.
|
Information and access to any and all tools associated with source code management and what mechanisms are used to manage the release process (this includes source trees, release version trees, iteration trees, etc. related to source code management).
|
ii.
|
A complete versioning diagram (individual trees) of release 2.x or the most current release.
|
e.
|
Contact information for the primary point of contact, Chief Technology Officer or designee.
|
f.
|
Source Code
|
i.
|
Shall include all source from Release 2.2 or current 2.x version
|
ii.
|
All source code files, libraries, and any and all necessary build items to completely build a full release, including but not limited to, .c, ,cpp, .h, .java, types of files. It should be in the form of an export from their source code version control so Convergys can import it and have a history of changes etc.
|
g.
|
Component Dependencies
|
i.
|
Any necessary files or compilation dependencies needed to build a successful release from the deposited media. This includes a complete list of any/all linked dependencies or files that need compiled first prior to linking.
|
h.
|
Build Environment Setup and Configuration
|
i.
|
Detailed instructions for configuration of build environment; including, but not limited to, configuration settings for all compilers and third party components. For example, does the build process expect the source code to be loaded to a specific location?
|
ii.
|
Any and all environment variables and parameters required to be set prior to running a build, specified explicitly for release 2.2 through the current 2.x release.
|
i.
|
Build Control Files
|
i.
|
Any and all files and/or scripts that control the build process. For example, Makefiles on UNIX systems, ‘.dsp’ and ‘.dsw’ in visual C++, or simple ‘.bat’ files. This may vary depending upon O/S and tools used, and include any batch or shell scripts that are used to control the build of the software.
|
j.
|
Any third-party applications, APIs, or other tools
|
i.
|
Any compilers, linkers, third party libraries, assemblers, pre-processors, post-processors, linkers, whether developed by Vendor or by third parties. Note: if these materials cannot be deposited due to licensing restrictions, Vendor should provide for each release deposited the names of all required applications, release number – including any patch or service pack number, vendor name and contact information (including website) of all required items.
|
ii.
|
Vendor shall provide the details on the version control system (i.e. Team foundation server, Visual Source Safe, etc.) and the defect tracking system in use to support the Source Code.
|
k.
|
Build Instructions
|
i.
|
Detailed instructions/sequence of actions describing how to compile the escrow deposit and build executables including the description of any required hardware or operating system requirements (including non-standard settings).
|
ii.
|
A verification of the build environment using the setup, specific instructions for performing the build should be included. If specific batch or shell scripts must be run to perform a build these should be identified with their location and any specific order of execution requirements.
|
iii.
|
Care should be taken to ensure that no ‘institutional knowledge’ is assumed in the build instructions as the person performing the build will not have this knowledge nor any reliable means to acquire it.
|
l.
|
Design Documentation
|
i.
|
Documentation providing a reasonably skillful programmer with information regarding source code architecture, overall design of the source code and interactions among modules for each release deposited.
|
m.
|
API’s/program interface documentation
|
i.
|
Specifications for any API’s that are exposed by the application(s), including any documentation which might reasonable be required by developers during design, code, test or maintenance phase of the software life-cycle as well as any and all APIs required by third-party tools or libraries that are required for a complete build of the application.
|
n.
|
Test Diagnostics
|
i.
|
Regression tests including automated scripts and test data for all releases for all releases deposited.
|
ii.
|
Identification of applications used for testing such as mainframe, Clarify, Siebel etc.
|
iii.
|
A detailed test plan including a detailed test plan documentation.
|
o.
|
Defect Tracking Repository
|
i.
|
A current extract of the defects tracking repository. It should be in the form of an export from their defect tracking system so Convergys can import it for easier review.
|
2.
|
Data/Database Information
|
a.
|
Data
|
i.
|
Sample/examples of any data or databases required to run the application(s), including data used for regression testing. Convergys is responsible for the purchase of database licenses necessary to run the software
|
b.
|
Database Schema/Data model documents
|
i.
|
Details of database schema and design information, including any necessary SQL files to create and/or backup files required to configure a database suitable for supporting compilation of the software and/or supporting the run-time function of the software.
|
3.
|
Runtime/Production Information
|
a.
|
Third party libraries, dll’s, applications, scripts (xml, html, etc.) and data required to establish the “live” environment
|
i.
|
A detailed listing, including names of all required applications, number – with patch or service pack number, vendor name and contact information (including website), and copies of all exe’s, third party libraries, data and test diagnostics required to establish a live environment.
|
b.
|
Hosting Configuration Instructions
|
i.
|
A list of detailed steps necessary to configure environment hosting executable code.
|
c.
|
Runtime/Production Environment configuration instructions
|
i.
|
Information regarding operating systems and diagnostics, including instructions regarding installation of the application and steps required to load the application onto a production/runtime environment. This should include identification of all third party components required for production system as well as any configuration settings.
|
d.
|
User Manuals/Training guides
|
i.
|
All user and training manuals for each release deposited including end-user documentation as well as full training guides (if any) that describe proper end-user setup and configuration and any and all release notes associated with each release. This should include but not be limited to:
|
1.
|
Customer training materials.
|
2.
|
Internal training materials.
|
3.
|
Customer-facing documentation.
|
4.
|
Internal documentation, including field guides, sizing guides, etc.
|
5.
|
3rd-party documentation used in development.
|
1.
|
$600,000.00 due and payable upon the Effective Date of the Agreement.
|
2.
|
$300,000.00 due and payable upon the later of January 22, 2012 or the start of the Knowledge Transfer set forth in Exhibit C.
|
3.
|
$300,000.00 upon completion of the Knowledge Transfer as set for in Exhibit C and delivery of all the Deliverables or June 30, 2012, whichever comes first.
|
4.
|
Once Convergys has distributed more than 5000 Seats of the Product, additional license fees will be paid for and reported as follows
|
§
|
Months 1-12 of the Agreement: $250 one-time royalty fee per Seat
|
§
|
Months 13-24 of the Agreement: $185 one-time royalty fee per Seat
|
§
|
Months 25-36 of the Agreement: $125 one-time royalty fee per Seat
|
§
|
Months 37-48 of the Agreement: $62.50 one-time royalty fee per Seat
|
§
|
Months 49-60 of the Agreement: $25 one-time royalty fee per Seat
|
1.
|
Stage 1
|
·
|
Plan
|
o
|
On-site normal Cicero new developer hire training
|
·
|
Goal
|
o
|
Prepare CVG developers with enough background to participate in Cicero development sprints
|
o
|
Prepare architect with technical background to participate in Cicero development exercise
|
2.
|
Stage 2
|
·
|
Plan
|
o
|
Shadow development sprint activities: ~ 1 month
|
•
|
Assumption: Development of SOW integrating DDS to Cicero
|
•
|
Shadow sprint teams: No coding assumed in this stage
|
•
|
Match CVG developer 1 to 1 with Cicero development sprint team
|
•
|
Participate in all development activities-to meetings
|
•
|
Design and code reviews
|
•
|
Go-to meetings during actual code development
|
•
|
CVG FTE will compare before/after code changes for feature developed in sprint
|
o
|
Allow architect to float from sprint to sprint to get overall feel
|
·
|
Goals
|
•
|
Prepare CVG developer to begin code activities
|
•
|
Best practices, code layouts, module etc.
|
3.
|
Stage 3
|
·
|
Plan
|
o
|
Participate in development sprint activities: ~ 1 - 2 months
|
•
|
Mimic and participate in sprint teams: Coding assumed in this stage
|
•
|
Participate in all development activities-to meetings
|
•
|
Design and code reviews
|
•
|
Go-to meetings during actual code development
|
•
|
Sprint lead will assign development project to CVG developer
|
•
|
Not designed as a deliverable (parallel development on same function as Cicero sprint lead)
|
•
|
Sprint lead will perform code review with CVG on his code
|
•
|
Compare with how Cicero completed code
|
o
|
Allow architect to float from sprint to sprint to get overall feel
|
·
|
Goals
|
o
|
Prepare CVG developer to begin deliverable coding activities
|
4.
|
Stage 4
|
·
|
Plan
|
o
|
Participate in development sprint activities: ~ 2-3 months
|
•
|
Participate in sprint teams: Coding assumed in stage
|
•
|
Participate in all development activities-to meetings
|
•
|
Design and code reviews
|
•
|
Go-to meetings during actual code development
|
•
|
Sprint lead will assign development project to CVG developer
|
•
|
Expectations are that this is a deliverable
|
•
|
Expect assignments to progressively become more complex
|
•
|
May start off as TR code fixes from previous sprints
|
o
|
Allow architect to float from sprint to sprint to get overall feel
|
·
|
Goals
|
o
|
CVG developer can maintain and enhance code
|
5.
|
Stage 5
|
·
|
Plan
|
o
|
At appropriate time Convergys test engineer will work with Cicero testing staff
|
•
|
Review and learn all Cicero test cases
|
•
|
Learn test procedures and best practices
|
o
|
Will shadow sprint testing activities for several sprints
|
o
|
Will shadow QA release activities
|
·
|
Goals
|
o
|
Prepare CVG test lead for testing sprints, maintenance releases and patches and major releases
|
·
|
Training for solution development and professional services personnel:
|
o
|
Cicero XM Foundations
|
o
|
Cicero XM Enterprise
|
·
|
Training for support personnel
|
o
|
Cicero XM Support
|
·
|
Services:
|
o
|
Vendor will provide Services as mutually agreed in a separate Professional Services Agreement or Statement of Work (SOW)
|
o
|
Convergys may purchase Services at the annually published Vendor Professional Services Rate Card less a 25% discount on the Daily Rate
|
o
|
Vendor will invoice Convergys for Services and reasonable travel and expenses; invoices for Services and travel expenses will be paid by Convergys within forty five (45) days of invoice
|
Service
|
Description
|
Daily Rate
|
Convergys Rate
|
XM Implementation and Consulting
|
Implementation Specialist
|
$1,600
|
$1,200
|
XM Planning and Management
|
Implementation / Project Manager
|
$1,600
|
$1,200
|
Amount: _____________
|
Date: ____________ |
1.
|
the Maker failed to make payment on time or in the amount due, which failure continues uncured ten (10) days after Maker’s receipt of written notice from the Lender specifying such failure; or
|
2.
|
the Maker goes into bankruptcy, whether through the Maker’s own choice or not, or makes an assignment for the benefit of creditors, or admits his inability to pay his debts as they become due.
|
1.
|
the Lender may, without further notice, accelerate the due date on this Note and all unpaid principal, interest, and all other charges immediately shall be due and payable;
|
2.
|
the Lender may demand additional security or that new parties become obligated to pay this note;
|
3.
|
the Lender may make use of any remedy the Lender has under state or federal law; and
|
4.
|
the Lender may make use of any remedy given to the Lender in any agreement securing or entered into in connection with this Note.
|
(1)
|
except as expressly provided in this Note, demand payment of amounts due (presentation);
|
(2)
|
obtain official certification of nonpayment (protest); or
|
(3)
|
except as expressly provided in this Note, give notice that the amounts due have not been paid (notice of dishonor).
|
If to Maker: |
Cicero, Inc.
8000 Regency Parkway
Suite 542
Cary, North Carolina 27518
Attn: John Broderick
Fax: (919) 380-5121
|
||
If to Lender: | John L. Steffens | ||
CICERO, INC.
|
|||
|
By:
|
||
John Broderick | |||
Chief Executive and Chief Financial Officer
|
|||
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
a)
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b)
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;
|
|
c)
|
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
|
|
d)
|
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
|
a)
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
b)
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
Date: April 16, 2012
|
By:
|
/s/ John P. Broderick | |
John P. Broderick | |||
Chief Executive Officer |
2.
|
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4.
|
I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
a)
|
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
|
b)
|
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;
|
|
c)
|
evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based upon such evaluation; and
|
|
d)
|
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5.
|
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
|
|
a)
|
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
|
|
b)
|
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.
|
Date: April 16, 2012
|
By:
|
/s/ John P. Broderick | |
John P. Broderick | |||
Chief Financial Officer |
|
(1)
|
The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
|
|
(2)
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented in the Report.
|
April 16, 2012 | By: /s/ John P. Broderick |
|
John P. Broderick
|
||
Chief Executive and Financial Officer
|
||
(Principal Financial and Accounting Officer)
|